[go: up one dir, main page]

WO2000054803A2 - Acides nucleiques immunostimulants et antigenes - Google Patents

Acides nucleiques immunostimulants et antigenes Download PDF

Info

Publication number
WO2000054803A2
WO2000054803A2 PCT/US2000/007213 US0007213W WO0054803A2 WO 2000054803 A2 WO2000054803 A2 WO 2000054803A2 US 0007213 W US0007213 W US 0007213W WO 0054803 A2 WO0054803 A2 WO 0054803A2
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
peptides
ige
allergens
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/007213
Other languages
English (en)
Other versions
WO2000054803A3 (fr
Inventor
Howard B. Sosin
Michael J. Caplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seer Pharmaceuticals LLC
Original Assignee
Panacea Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharmaceuticals LLC filed Critical Panacea Pharmaceuticals LLC
Priority to AU37601/00A priority Critical patent/AU3760100A/en
Publication of WO2000054803A2 publication Critical patent/WO2000054803A2/fr
Publication of WO2000054803A3 publication Critical patent/WO2000054803A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Definitions

  • the present invention is generally in the area of immunomodulatory methods and compositions and in particular relates to methods and compositions for treating or preventing allergies.
  • This application is related to U.S.S.N. 60/169.330 entitled •• Controlled Delivery of Antigens" filed Dec. 6. 1999: U.S.S.N. 09/141 ,220 entitled “Methods and Reagents for Decreasing Clinical Reaction to Allergy” filed Aug. 27. 1998; U.S.S.N. 09/455.294 entitled “Peptide Antigens” filed December 6, 1999: US
  • Allergic reactions result when an individual's immune system overreacts, or reacts inappropriately, to an encountered antigen.
  • an individual typically, there is no allergic reaction the first time an individual is exposed to a particular antigen.
  • the antigen is taken up by antigen presenting cells (APC; e.g.. macrophages and dendritic cells) that degrade the antigen and then display antigen fragments to T cells.
  • APC antigen presenting cells
  • T cells in particular CD4 T "helper" T-cells. respond by secreting a collection of cytokines that have effects on other immune system cells.
  • the profile of cytokines secreted by responding CD4 + T cells determines whether subsequent exposures to the antigen will induce allergic reactions.
  • Two classes of CD4 * T cells (Thl and Th2: T-lymphocyte helper type) influence the type of immune response that is mounted against an antigen.
  • Thl -type immune response involves the stimulation of cellular immunity to antigens and infectious agents and is characterized by the secretion of IL-2.
  • IL-6 is characterized by the secretion of IL-6.
  • IL-12 IFN ⁇ , and TNF ⁇ by CD4 * T helper cells and the production of IgG antibodies. Exposure of CD4 * T cells to antigens can also activate the cells to develop into Th2 cells, which secrete IL-4. IL-5. IL-10 and IL-13.
  • One effect of IL-4 production is to stimulate the maturation of B cells that produce IgE antibodies specific for the antigen.
  • These antigen-specific IgE antibodies attach to receptors on the surface of mast cells, basophils and eosinophils. where they act as a trigger to initiate a rapid immune response to the next exposure to antigen. When the individual encounters the antigen a second time, the antigen is quickly bound by these surface-associated IgE molecules.
  • Each antigen typically has more than one IgE binding site, so that the surface-bound IgE molecules quickly become crosslinked to one another through their simultaneous (direct or indirect) associations with antigen. Such cross-linking induces mast cell degranulation. resulting in the release of histamines and other substances that trigger allergic reactions. Individuals with high levels of IgE antibodies are known to be particularly prone to allergies.
  • the Thl and Th2-type responses are antagonistic. In other words, one response inhibits secretions characterized by the other immune response.
  • therapies to control the Thl and Th2-mediated immune responses are highly desirable to control immune responses to allergenic agents and to infectious agents.
  • Current treatments for allergies involve attempts to "vaccinate" a sensitive individual against a particular allergen by periodically injecting or treating the individual with a crude suspension of the raw allergen.
  • the goal, through controlled administration of known amounts of antigen, is to modulate the IgE response mounted in the individual. If the therapy is successful, the individual's IgE response is diminished, or can even disappear.
  • the therapy requires several rounds of vaccination, over an extended time period (3-5 years), and very often does not produce the desired results.
  • certain individuals suffer anaphylactic reactions to the vaccines, despite their intentional, controlled administration.
  • the present invention provides methods and compositions for modulating an individual's immune response to antigens. It is an aspect of the present invention that allergic responses to antigens, which in some cases lead to asthma and even anaphylaxis, can be treated or prevented by administering compositions having immunostimulatory oligonucleotides including unmethylated CpG sequences. It is another aspect of the present invention that allergies to antigens, especially ones that result in asthma and/or anaphylaxis. can be treated or prevented by administering compositions containing immunostimulatory oligonucleotides having unmethylated
  • CpG dinucleotide sequences and further comprising antigen(s). fragments of the antigen, mixtures of fragments of the antigen, antigens modified to reduce Th2-type immune responses, and fragments of the antigen modified to reduce Th2-type immune responses.
  • Cellular systems for studying immunostimulation by CpG containing nucleic acids include in vivo, in vitro or ex vivo systems.
  • composition comprising an oligonucleotide comprising a nucleotide sequence 5' purine-purine-C-G-pyrimidine- pyrimidine 3' wherein C and G are unmethylated and further comprising at least one antigen derived from an allergen that causes anaphylaxis is used to treat or prevent allergies in individuals.
  • the antigen is derived from the group consisting of food allergens, venom allergens, latex allergens, and drug allergens.
  • the antigen is a peptide. polypeptide. or protein.
  • the least one antigen comprises a collection of peptides.
  • the collection of peptides can have amino acid sequences that overlap.
  • the collection of peptides can have amino acid sequences that do not overlap.
  • the collection of peptides does not have peptides with more than one IgE binding site.
  • the antigen is a polypeptide
  • the polypeptide has an amino acid sequence derived from a protein found in foods such as nuts, milk, eggs, seafood and wheat.
  • peptides, polypeptides and proteins of the present invention can be modified to reduce the binding affinity to IgE antibodies.
  • a method of treating or preventing allergies and allergies leading to anaphylaxis in individuals is provided.
  • Compositions comprising immunostimulatory oligonucleotides that include unmethylated CpG dinucleotides and also comprising at least one antigen derived from an allergen are administered to individuals who suffer from allergies and allergic reactions that include anaphylaxis.
  • the allergens are food allergens, venom allergens, latex allergens, and drug allergens. More preferably, the antigens are peptides. polypeptides or proteins although drugs include non-peptide compounds such as penicillin. Preferably, but not necessarily, peptides. polypeptides and proteins of the present invention are modified to reduce the binding affinity to IgE antibodies.
  • the antigens are collections of peptides having amino acid sequences derived from protein allergens that cause allergies and in some cases, anaphylaxis. The peptides can have overlapping amino acid sequences or the peptides can have amino acid sequences that do not overlap.
  • immunostimulator ' oligonucleotides include unmethylated CpG dinucleotides in sequence contexts which include 5' TCAACGTT 3'. 5' GACGTT 3'. 5' AGCGTT 3' , 5' AACGCT 3', 5' AACGAT 3'. 5' TCAACGTT 3', 5' GACGTT 3'. 5' AGACGT 3', 5' AACGCT 3', 5' TGACGTT 3'. 5' TAGACGT 3'. 5' TAACGCT 3', 5' TCGTCGTTTT 3'. and 5'
  • compositions comprising immunostimulatory oligonucleotides of the present invention conjugated to non-allergenic compound.
  • the conjugation of the oligonucleotide to non-allergic compounds improves the uptake of the nucleic acids by cells related to the immune system such as leukocytes and lymphocytes.
  • the compositions are administered to individuals with allergies to shift an immune response towards a Thl -type immune response.
  • compositions comprising antigens, modified antigen and/or collections of antigens are administered to the individuals with Thl stimulated immune responses.
  • individuals with immune systems stimulated Thl- type response can have additional compositions comprising additional antigens. modified antigens and/or collection of antigens administered.
  • compositions comprising immunostimulatory oligonucleotides including unmethylated CpG dinucleotides and at least one antigen derived from allergens that cause allergies and allergies associated with anaphylaxis are provided.
  • An “allergen” is an antigen that (i) elicits an IgE response in an individual; and/or (ii) elicits an asthmatic reaction (e.g.. chronic airway inflammation characterized by eosinophilia. airway hyperresponsiveness. and excess mucus production), whether or not such a reaction includes a detectable IgE response).
  • an asthmatic reaction e.g.. chronic airway inflammation characterized by eosinophilia. airway hyperresponsiveness. and excess mucus production
  • Preferred allergens for the purpose of the present invention are protein allergens. although the invention is not limited to such.
  • An exemplary list of protein allergens is presented as an Appendix. This list was adapted on July 22. 1999. from ftp://biobase.dk pub/who-iuis/allergen.list. which provides lists of known allergens.
  • Allergic reaction An allergic reaction is a clinical response by an individual to an antigen. Symptoms of allergic reactions can affect cutaneous (e.g.. urticaria, angioedema. pruritus), respiratory (e.g., wheezing, coughing, laryngeal edema, rhinorrhea. watery/itching eyes) gastrointestinal (e.g., vomiting, abdominal pain, diarrhea), and/or cardiovascular (if a systemic reaction occurs) systems.
  • cutaneous e.g.. urticaria, angioedema. pruritus
  • respiratory e.g., wheezing, coughing, laryngeal edema, rhinorrhea. watery/itching eyes
  • gastrointestinal e.g., vomiting, abdominal pain, diarrhea
  • cardiovascular if a systemic reaction occurs
  • An “anaphylactic antigen” is an antigen that is recognized to present a risk of anaphylactic reaction in allergic individuals when encountered in its natural state, under natural conditions.
  • pollens and animal danders or excretions e.g.. saliva, urine
  • food antigens, insect antigens, drugs, and rubber e.g.. latex
  • antigens latex are generally considered to be anaphylactic antigens.
  • Food antigens are particularly preferred anaphylactic antigens for use in the practice of the present invention.
  • Particularly interesting anaphylactic antigens are those (e.g.. nuts, seeds, seafood, venom) to which reactions are commonly so severe as to create a risk of death.
  • Anaphylaxis refers to an immune response characterized by mast cell degranulation secondary to antigen- induced cross-linking of the high-affinity IgE receptor on mast cells and basophils with subsequent mediator release and the production of pathological responses in target organs, e.g.. airway, skin, digestive tract and cardiovascular system.
  • target organs e.g. airway, skin, digestive tract and cardiovascular system.
  • the severity of an anaphylactic reaction may be monitored, for example, by assaying cutaneous reactions, puffiness around the eyes and mouth, and/or diarrhea, followed by respiratory reactions such as wheezing and labored respiration. The most severe anaphylactic reactions can result in loss of consciousness and/or death.
  • Antigen is (i) any compound or composition that elicits an immune response; and/or (ii) any compound that binds to a T cell receptor (e.g.. when presented by an MHC molecule) or to an antibody produced by a B-cell.
  • an antigen may be collection of different chemical compounds (e.g.. a crude extract or preparation) or a single compound (e.g.. a protein).
  • Preferred antigens are protein antigens, but antigens need not be proteins for the practice of the present invention.
  • association When two entities are “associated with” one another as described herein, they are linked by a direct or indirect covalent or non-covalent interaction. Preferably, the association is covalent. Desirable non-covalent interactions include, for example, hydrogen bonding, van der Waals interaction. hydrophobic interaction, magnetic interaction, etc.
  • an antigen “fragment” is any part or portion of the antigen that is smaller than the entire, intact antigen.
  • the antigen is a protein and the fragment is a peptide.
  • IgE binding site An IgE binding site is a region of an antigen that is recognized by an anti-antigen IgE molecule. Such a region is necessary and/or sufficient to result in (i) binding of the antigen to IgE; (ii) cross-linking of anti-antigen IgE; (iii) degranulation of mast cells containing surface-bound anti-antigen IgE; and/or (iv) development of allergic symptoms (e.g., histamine release).
  • IgE binding sites are defined for a particular antigen or antigen fragment by exposing that antigen or fragment to serum from allergic individuals (preferably of the species to whom inventive compositions are to be administered). It will be recognized that different individuals may generate IgE that recognize different epitopes on the same antigen. Thus, it is typically desirable to expose antigen or fragment to a representative pool of serum samples. For example, where it is desired that sites recognized by human IgE be identified in a given antigen or fragment, serum is preferably pooled from at least 5-10. preferably at least 15. individuals with demonstrated allergy to the antigen. Those of ordinary skill in the art will be well aware of useful pooling strategy in other contexts. "Immunodominant": A particular epitope is considered to be
  • immunodominant if it (i) is responsible for a significant fraction of the IgE binding observed with the intact antigen: (ii) is recognized by IgE in a significant fraction of sensitive individuals; and/or (iii) is a particularly high affinity site.
  • An immunodominant epitope is often defined in reference to the other observed epitopes. For example, all IgE epitopes in a given antigen can be assayed simultaneously (e.g.. by immunoblot) and the immunodominant epitopes can be identified by their strength as compared with the other epitopes. Usually, but not always, an immunodominant epitope will contribute at least 10% of the binding reactivity observed in such a stud ⁇ .
  • an epitope can be classified as immunodominant if it is recognized by IgE in sera of a significant fraction, preferably at least a majority, more preferably at least about 60%. 70%. 80%. 90%. 95%. 99%. or 100%. of sensitive individuals.
  • Immunostimulatory oligonucleotide nucleic acid molecules contain unmethylated CpG dinucleotides that stimulate vertebrate lymphocytes and are any length. Preferred immunostimulatory oligonucleotides are between approximately 2 to 100 nucleotides in size. Immunostimulatory oligonucleotides can be single stranded or double stranded. Immunostimulatory oligonucleotides can also contain deoxyribonucleic acids and/or ribonucleic acids. Particularly preferred immunostimulatory oligonucleotides are double-stranded and are approximately 5-50 base pairs in length.
  • mast cell As will be apparent from context, the term “mast cell” is often used herein to refer to one or more of mast cells, basophils. and other cells with IgE receptors.
  • oligonucleotide shall mean multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)).
  • a substituted pyrimidine e.g. cytosine (C), thymine (T) or uracil (U)
  • a substituted purine e.g. adenine (A) or guanine (G)
  • a “peptide” comprises a string of at least three amino acids linked together by peptide bonds.
  • Inventive peptides preferably contain only natural amino acids, although non-natural amino acids (i.e.. compounds that do not occur in nature but that can be incorporated into a polypeptide chain; see, for example. http://www.cco.caltech.edu ⁇ dadgrp/Unnatstruct.gif. which displays structures of non-natural amino acids that have been successfully incorporated into functional ion channels) and/or amino acid analogs as are known in the art may alternatively be employed.
  • amino acids in an inventive peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization. or other modification, etc.
  • a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization. or other modification, etc.
  • an inventive composition or antigen fragment is considered to have "reduced IgE binding" if it demonstrates a lower level of interaction with IgE when compared with intact antigen in any available assay.
  • an antigen fragment is considered to have reduced IgE binding if (i) its affinity for anti-antigen IgE (assayed, for example, using direct binding studies or indirect competition studies) is reduced at least about 2-5 fold, preferably at least about 10, 20. 50. or 100 fold as compared with intact antigen ; (ii) ability of the fragment to support cross-linking of anti-antigen IgE is reduced at least about 2-fold. preferably at least about 5. 10, 20, 50, or 100 fold as compared with intact antigen;
  • mast cells containing surface-bound anti-antigen IgE degranulate less (at least about 2 fold, preferably at least about 3. 5, 10. 20. 50. or 100 fold less) when contacted with fragment as compared with intact antigen: and/or (iv) individuals contacted with fragment develop fewer (at least about 2 fold, preferably at least about 3. 5, 10, 20, 50, or 100 fold fewer) allergic symptoms, or developed symptoms are reduced in intensity) when exposed to fragment as compared with intact antigen.
  • Sensitized mast cell A “sensitized " mast cell is a mast cell that has surface-bound antigen specific IgE molecules. The term is necessarily antigen specific. That is. at any given time, a particular mast cell will be “sensitized” to certain antigens (those that are recognized by the IgE on its surface) but will not be sensitized to other antigens.
  • Subject A “subject” as used herein is defined as a human or vertebrate animal including without limitation a dog. cat. horse, cow, pig. sheep, goat, chicken, monkey, rat. mouse, rabbit etc.
  • "Susceptible individual” a person is susceptible to a severe and/or anaphylactic allergic reaction if (i) that person has ever displayed symptoms of allergy after exposure to a given antigen; (ii) members of that person ' s genetic family have displayed symptoms of allergy against the allergen, particularly if the allergy is known to have a genetic component; and/or (iii) antigen- specific IgE are found in the individual, whether in serum or on mast cells.
  • Thl response and Th2 response Certain preferred peptides. polypeptides. proteins, immunostimulatory nucleic acids and compositions of the present invention are characterized by their ability to suppress a Th2 response and/or to stimulate a Thl response preferentially as compared with their ability to stimulate a Th2 response.
  • Thl and Thl responses are well-established alternative immune system responses that are characterized by the production of different collections of cytokines and/or cofactors.
  • Thl responses are generally associated with production of cytokines such as IL-l ⁇ , IL-2. IL-6, IL-12. IL-18, IFN ⁇ . IFN ⁇ , TNF ⁇ . etc:
  • Th2 responses are generally associated with the production of cytokines such as IL-4.
  • T cell subset suppression or stimulation may be determined by any available means including, for example, intra-cytoplasmic cytokine determination.
  • Th2 suppression is assayed, for example, by quantitation of IL-4. IL-5. and/or IL-13 in stimulated T cell culture supernatant or assessment of T cell intra-cytoplasmic (e.g.. by protein staining or analysis of mRNA) IL-4, IL-5. and/or IL-13;
  • Thl stimulation is assayed. for example, by quantitation of IFN ⁇ , IFN ⁇ . IL-2, IL-12. and/or IL-18 in activated T cell culture supernatant or assessment of intra-cytoplasmic levels of these cytokines.
  • the present invention provides methods and compositions for modulating an individual ' s immune response to antigens. It is an aspect of the present invention that allergic responses to antigens, which in some cases lead to asthma and even anaphylaxis. can be treated or prevented by administering compositions having immunostimulatory oligonucleotides including unmethylated CpG sequences. It is another aspect of the present invention that allergies to antigens, especially ones that result in asthma and/or anaphylaxis. can be treated or prevented by administering compositions containing immunostimulatory oligonucleotides having unmethylated
  • CpG dinucleotide sequences and further comprising antigen(s). fragments of the antigen, mixtures of fragments of the antigen, antigens modified to reduce Th2-type immune responses, and fragments of the antigen modified to reduce Th2-type immune responses.
  • Cellular systems for studying immunostimulation by CpG containing nucleic acids include in vivo, in vitro or ex vivo systems.
  • any oligonucleotide molecule that stimulates an immune response to antigens to elicit a Th 1 -type immune response may be used in accordance with the present invention.
  • Preferred immunostimulatory oligonucleotides for use in the present invention include any nucleic acid molecules having an unmethylated dinucleotide sequence of CpG. Particularly preferred CpG containing-sequences are palindromic and have the generic sequence of 5' purine-purine-cytosine-guanine- pyrimidine-pyrimidine.
  • Unmethylated CpG-containing DNA induce a predominantly Thl pattern of immune activation characterized by the production of IL-6, IL-12 and IFN- ⁇ in cells.
  • oligonucleotides containing CpG repeats are effective in stimulating an immune response when the CpG dinucleotide is unmethylated and present within a particular sequence context.
  • the sequence context that has been reported to be most effective is CpG flanked by two purines on the 5' end and two pyrimidines on the 3' end (5'-Pur-Pur-C-G-Pyr-Pyr-3': see U.S. Patent No. 5.830.877:
  • immunostimulatory sequences of the present invention include but are not limited to (5' to 3') AACGCC. AACGCG, AACGGC. AACGGG, ATCGCC. ATCGCG, ATCGGC, ATCGGG. TACGCC, TACGCG. TACGGC. TACGGG. TTCGCC, TTCGCG, TTCGGC. TTCGGG.
  • Preferred immunostimulatory sequences are described by USP 6.008.200 and include 5' TCAACGTT 3'. 5' GACGTT 3'. 5' AGCGTT 3' . 5' AACGCT 3'. and 5'
  • AACGAT 3' wherein the CpG dinucleotides are unmethylated. More preferred are immunostimulatory oligonucleotides having the sequences 5' TCAACGTT 3', 5' GACGTT 3'. 5' AGACGT 3'. or 5' AACGCT 3' with a T nucleotide adjacent to the sequences at the 5' end. Particularly preferred immunostimulatory sequences containing unmethylated
  • Oligonucleotides containing a nuclease resistant phosphorothioate backbone were approximately 200 times more potent as immunostimulatory nucleic acids than unmodified oligonucleotides as measured by lymphocyte activation using mouse spleen cells.
  • the presence of the phosphorothioate backbone inhibits nuclease digestion which occurs in the serum of subjects treated with immunostimulatory oligonucleotides or occurs intracellularly. Degradation of the oligonucleotides occurs through digestion by 5' and 3' exonucleases and numerous endonucleases.
  • Oligonucleotides for use in accordance with the present invention include any naturally occurring or non-naturally occurring nucleic acids.
  • One of ordinary skill in the art will recognize that many modifications to bases, sugars, and phosphodiester linkages have been made in the literature and that future modifications will also be performed.
  • Nucleic acids for use in accordance with the present invention also include any nucleic acid for use in gene therapy.
  • Oligonucleotides of the present invention preferably contain naturally occurring nucleotides. However, modifications to nucleotides. bases, sugars, and phosphodiester backbone that are in accordance with the present invention are also acceptable and in some cases desirable. For example, it has been shown that immunostimulatory oligonucleotides having nuclease resistant phosphorothioate linkages at the ends of the oligos have immunostimulatory effects that are approximately 20 times stronger than oligo that have all naturally occurring phosphodiester linkages.
  • Oligonucleotides are polymers of nucleosides joined, generally, through phosphoester linkages.
  • a nucleoside consists of a purine (adenine or guanine or derivative thereof) or pyrimidine (thymine. cytosine or uracil, or derivative thereof) based bonded to a sugar.
  • the four nucleoside units (or bases) in DNA are called deoxyadenosine, deoxyguanosine. deoxythymidine. and deoxycytidine.
  • a nucleotide is a phosphate ester of a nucleoside.
  • the oligonucleotide of the invention can comprise ribonucleotides (containing ribose as the only or principal sugar component), deoxyribonucleotides (containing deoxyribose as the principal sugar component), or. in accordance with the state of the art, modified sugars or sugar analogs can be incorporated in the immunostimulatory oligonucleotides.
  • the sugar moiety can be pentose. deoxypentose. hexose. deoxyhexose. glucose, arabinose. xylose, lyxose. and a sugar "analog" cyclopentyl group.
  • the sugar can be in pyranosyl or in a furanosyl form.
  • the sugar moiety is preferably the furanoside of ribose. deoxyribose. arabinose or 2 " -0-methylribose, and the sugar can be attached to the respective heterocvclic bases either in ⁇ or ⁇ anomeric configuration.
  • the preparation of these sugars or sugar analogs and the respective "nucleosides " wherein such sugars or analogs are attached to a heterocvclic base (nucleic acid base) per se is known, and need not be described here, except to the extent such preparation can pertain to any specific example.
  • the phosphorous derivative (or modified phosphate group) which can be attached to the sugar or sugar analog moiety in the oligonucleotides of the present invention can be a monophosphate. diphosphate. triphosphate. alkylphosphate, alkanephosphate. phosphorothioate, phosphorodithioate or the like. A phosphorothioate linkage can be used in place of a phosphodiester linkage.
  • the preparation of the above-noted phosphate analogs, and their incorporation into nucleotides. modified nucleotides and oligonucleotides, per se. is also known and need not be described here in detail. Peyrottes et al. (1996) Nucleic Acids Res.
  • oligonucleotides of the present invention comprise phosphorothioate linkages. Oligonucleotides with phosphorothioate backbones can be more immunogenic than those with phosphodiester backbones and appear to be more resistant to degradation after injection into the host. Braun et al. (1988) J. Immunol 141 :2084-2089; and Latimer et al. (1995) Mol Immunol. 32: 1057-1064.
  • heterocyclic bases, or nucleic acid bases, which are incorporated in the immunostimulatory oligonucleotides can be the naturally-occurring principal purine and pyrimidine bases, (namely uracil or thymine, cytosine, adenine and guanine. as mentioned above), as well as naturally-occurring and synthetic modifications of said principal bases.
  • the immunostimulatory oligonucleotides can include one or several heterocyclic bases other than the principal five base components of naturally-occurring nucleic acids.
  • the heterocyclic base in the immunostimulatory oligonucleotides includes, but is not limited to. uracil-5-yl, cytosin-5-yl. adenin-7-yl. adenin-8-yl. guanin-7-yl.
  • guanin-8-yl 4-aminopyrrolo [2.3- d] pyrimidin-5-yl, 2-amino-4-oxopyrolo [2.3-d] pyrimidin-5-yl, 2-amino-4- oxopyrrolo [2.3-d] pyrimidin-3-yl groups, where the purines are attached to the sugar moiety of the immunostimulatory oligonucleotides via the 9-position. the pyrimidines via the 1 -position, the pyrrolopyrimidines via the 7-position and the pyrazolopyrimidines via the 1 -position.
  • the immunostimulatory oligonucleotides comprises at least one modified base.
  • modified base is synonymous with “base analog”, for example, "modified cytosine " is synonymous with “cytosine analog.”
  • modified nucleosides or nucleotides are herein defined as being synonymous with nucleoside or nucleotide “analogs.”
  • a cytosine of the immunostimulatory oligonucleotides is substituted with a cytosine modified by the addition to C-5 and/or C-6 on cytosine with an electron-withdrawing moiety.
  • the electron-withdrawing moiety is a halogen.
  • modified cytosines can include, but are not limited to. azacytosine. 5-bromocytosine, bromouracil. 5-chlorocytosine. chlorinated cytosine. cyclocytosine, cytosine arabinoside, fluorinated cytosine, fluoropyrimidine. fiuorouracil, 5.6-dihydrocytosine, halogenated cytosine. halogenated pyrimidine analogue, hydro xyurea, iodouracil. 5- nitrocytosine. uracil. and any other pyrimidine analog or modified pyrimidine.
  • oligonucleotides can be synthesized using any of a number of procedures well known in the art. For example, the ⁇ -cyanoethyl phosphoramidite method (S. L. Beaucage and M. H. Caruthers, (1981) Tet. Let.
  • nucleoside H-phosphonate method (Garegg et al.. (1986) Tet. Let. 27: 4051-4054; Froehier et al.. (1986) Nucl. Acid. Res. 14: 5399-5407; Garegg et al.. (1986) Tet. Let. 27: 4055-4058. Gaffney et al.. (1988) Tet. Let. 29:2619-2622).
  • the methods of nucleic acid synthesis can be performed by a variety of automated oligonucleotide synthesizers which are commercially available (for example see PE
  • oligonucleotides can be prepared from existing nucleic acid sequences (e.g. genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases (Ausubel et al. "Current Protocols in Molecular Biology " . Wiley & Sons; incorporated herein by reference).
  • oligonucleotides are preferably relatively resistant to degradation by factors and conditions such as acidic conditions, endonucleases and exonucleases. Oligonucleotide stabilization can be accomplished via phosphate backbone modifications.
  • a preferred stabilized oligonucleotide has a phosphorothioate modified backbone.
  • the pharmacokinetics of phosphorothioate oligonucleotides show that they have a systemic half-life of forty-eight hours in rodents and suggest that they may be useful for in vivo applications (Agrawal. S. et al. (1991) Proc. Natl. Acad. Sci. USA 88:7595).
  • Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H phosphonate chemistries.
  • Aryl- and alkyl-phosphonates can be made e.g. (as described in U.S. Pat. No.
  • alkylphosphotriesters in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023.243 and European Patent No. 092,574 can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman. A. (1990) Chem. Rev. 90:544; Goodchild. J. ( 1990) Bioconjugate Chem. 1 :165).
  • Immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides can be single stranded nucleic acids, or double stranded nucleic acids of any length. Preferred immunostimulatory oligonucleotides are between approximateh 2 to 100 nucleotides in size. Immunostimulatory oligonucleotides can also contain deoxyribonucleic acids and/or ribonucleic acids. Particularly preferred immunostimulatory oligonucleotides are double-stranded and are approximately 5-50 base pairs in length. Immunostimulatory oligonucleotides in accordance with the present invention can also be single-stranded or double-stranded circular nucleic acids, preferably DNA. Antigens
  • inventive compositions comprising immunostimulatory oligonucleotides also comprise immunomodulatory compounds including antigens, cytokines and adjuvants.
  • inventive compositions contain antigens, fragments of antigens, a collection of fragments of antigens, antigens modified to reduce binding to IgE. fragments of antigens or modified fragments of antigens that reduce binding to IgE antibodies, fragments of antigens to reduce crosslinking of IgE antibodies bound to mast cells and collections thereof.
  • antigen is used herein to describe any molecule or compound that elicits an immune response.
  • antigens include but are not limited to proteins, cytokines, viruses, viral particles, allergens, pollen, dust mite proteins, animal dander, fungal spores, interleukins. interferons. colony stimulating factors, synthetic peptides. polysaccharides. lipids. hormones, naturally occurring molecules with biological activity, and synthetic molecules with biological activity (for example without limitation, enzyme inhibitors. antiviral agents, anticancer agents, anticancer agents).
  • proteins include proteins, cytokines, viruses, viral particles, allergens, pollen, dust mite proteins, animal dander, fungal spores, interleukins. interferons. colony stimulating factors, synthetic peptides. polysaccharides. lipids. hormones, naturally occurring molecules with biological activity, and synthetic molecules with biological activity (for example without limitation, enzyme inhibitors. antiviral agents, anticancer agents, anticancer agents).
  • One of ordinary skill in the art will be able to identify antigens for use in the present invention.
  • antigens are peptides, polypeptides and proteins preferably having amino acid sequences derived from allergenic proteins found in foods, venom including insect and snake, rubber-base products, animal dander, plant pollen, insect allergens, and/or pharmaceutical drugs.
  • Antigens according to the present invention are provided in compositions comprising immunostimulatory oligonucleotides that include unmethylated CpG sequences.
  • Appendix A presents a representative list of certain known protein antigens. As indicated, the amino acid sequence is known for many or all of these proteins, either through knowledge of the sequence of their cognate genes or through direct knowledge of protein sequence, or both. Of particular interest are anaphylactic antigens.
  • the amino acid sequences of antigenic peptides, polypeptides and proteins are derived from food allergens.
  • protein allergens found in food include proteins found in nuts (e.g.. peanut, walnut, almond, pecan, cashew, hazelnut, pistachio, pine nut. brazil nut: for reviews see Tariq et al. British Med. J. 313:514-517. 1996; Rubira et al. Allerg Immunol. 30:212-216. 1998 both incorporated herein by reference), seafood (e.g. shrimp, crab, lobster, clams), fruit (e.g.
  • protein antigens found in pollen-related food allergies may be used (e.g. birch pollen related to apple allergies).
  • Other protein allergens found in foods include those found in young garlic (Allergy 54(6):626-9 (1999), and allergens found in snails (Arch Pediatr 4(8): 767-9 (1997)). Protein allergens in wheat are known to cause exercise-induced allergies (J Allergy Clin Immunol 1999
  • antigens are derived from compounds that cause anaphylactic allergic responses such as food allergies (peanut, milk. egg. wheat),, venoms, rubber-based products such as latex and drugs such as penicillin.
  • Many of these antigens are proteins that cause anaphylactic shock in individuals allergic to the proteins.
  • allergic reactions to nuts, shellfish, and bee venom are known to be severe enough to cause anaphylaxis.
  • Non-limiting examples of proteins in insect venom include phospholipase A found in bee venom (Weber et al. Allergy
  • anaphylactic antigens for use in accordance with the present invention are modified and/or fragmented to remove one or more IgE binding sites. This reduces the ability of the antigen to crosslinking IgE antibodies present on the surface of mast cells.
  • fragments of various inhaled antigens that may have reduced ability to bind and/or cross-link IgE, these are generally not anaphylactic antigens and do not present the same risks to sensitive individuals (see. for example. U.S. Patent No. 5.736.149; U.S. Patent No. 5,891 ,716; U.S. Patent No. 5.820.862; U.S. Patent No. 5.710.126; U.S. Patent No. 5.591.433; U.S. Patent No. 4.338,297; U.S. Patent No. 4.469.677; U.S. Patent No.
  • the IgE bindings sites for these peanut allergens were determined and modified through amino acid deletion, substitution or modification to remove the IgE binding sites (see for example U.S.S.N. 09/141,220 entitled “Methods and Reagents for Decreasing Clinical Reaction to Allergy” filed Aug. 27. 1998 which has been incorporated herein by reference).
  • the antigen(s) is a peptide or a collection of peptides having amino acid sequences that are derived from protein allergens found in foods, venom, drugs such as penicillin, rubber-based products such as latex, pollen, and insects such as mites and cockroaches.
  • a collection of peptides that represents substantially all of the structural features of a protein antigen is used.
  • substantially all of the structural elements of the protein antigen are represented in the peptide collection with substantially all of the peptides having no more than one IgE binding site present within each individual peptide. Therefore, the ability of the collection of peptides to crosslink IgE molecules bound to the surface of mast cells is reduced or eliminated.
  • antigenic compounds are provided in the form of peptide fragments whose amino acid sequences are derived from antigens that cause anaphylaxis in subjects who are allergic to them.
  • An antigen fragment according to the present invention is a portion of the antigen that is smaller than the intact antigen.
  • Inventive compositions including antigen fragments will preferably contain either a sufficiently large number of antigen fragments or at least one antigen fragment that is sufficiently sized that the composition contains one or more immunologically relevant structural element that is present in the intact antigen.
  • certain preferred inventive compositions include at least one of the antigen ' s T cell epitopes and preferably retain an ability to stimulate T cell proliferation.
  • the antigen is preferably a protein and the fragment is preferably a peptide.
  • Preferred peptides are at least 6 amino acids long; Particularly preferred peptides are at least about 10, 12, 15, 20, 25, or 30 amino acids long.
  • peptide antigen fragments have amino acid sequences that are identical to the amino acid sequences of the corresponding portions of the antigen.
  • such peptides having the natural antigen sequence are selected to have reduced IgE binding as compared with the intact antigen by virtue of (i) not including known dominant IgE binding sites; (ii) not including more than one intact IgE binding site; and/or (iii) containing no IgE binding sites.
  • peptide antigen fragments have amino acid sequences that differ from those of the corresponding portions of the antigen in that at least one effective IgE binding site in the intact antigen has been disrupted or removed.
  • Any of a variety of strategies may be employed to disrupt identified IgE biding sites.
  • chemical modifications may be made to amino acids (e.g.. to amino acid side chains) within the binding site so as to interfere with its interaction with an IgE molecule.
  • amino acids may be deleted, inserted, substituted, or stretches of amino acids may be inverted (see. for example. USSN 09/141.220 filed August 27. 1998. entitled “Methods and Reagents for Decreasing Clinical Reaction to Allergy, incorporated herein, by reference).
  • compositions comprising multiple antigen fragments.
  • the collection of antigen fragments represents substantially all of the primary structural features of the intact antigen (e.g.. at least about 40%. 50%. 60%, 70%. 75%. 80%. 90%. 95%. or 99% of the antigen primary structure) .
  • the collection represents substantially all such structural features other than one or more that include part or all of an IgE binding site.
  • the strategy of preparing antigen fragment collections that include substantially all of the primary structural features of the intact antigen represents a significant departure from accepted strategies of allergy reduction.
  • the primary accepted strategy previously has been to select a single fragment, or possibly a small number (fewer than five) of fragments having a selected activity (e.g., T cell stimulation and discarding all other structural information from the antigen (see, for example, U.S.
  • Example 3 describes the preparation of a collection of overlapping peptides that represent the entire amino acid sequence of a selected protein antigen;
  • Example 4 describes the use of this collection in an allergy vaccine composition in accordance with the present invention.
  • Those of ordinary skill in the art will recognize that such collections of overlapping peptides may be prepared for any protein antigen.
  • the length of the overlapping peptides is not essential to the invention, though it is generally preferred that the peptides be at least about 6. and more preferably at least about 10. amino acids long. In particularly preferred embodiments, the peptides are at least about 1 1. 12, 15, 20. 25. 30. 35. 40. 45. or 50 amino acids long.
  • the extent of overlap is not essential to the present invention, though it is generally preferred that the peptides are offset from one another by no more than about 20. and preferably no more than about 15 amino acids. In particularly preferred inventive compositions, the peptides are offset from one another by no more than about 10. 7. 6. 5, 4. 3. 2, or 1 amino acid. In certain preferred embodiments, a complete set of overlapping peptides is depleted for certain peptides. For example, peptides that contain dominant IgE binding sites may be removed (see Example 2). Alternatively or additionally, peptides that contain more than one IgE binding site may be removed. In other embodiments of the invention, all peptides containing an intact (or. in some embodiments, partial) IgE binding site can be removed; or all peptides containing IgE binding sites of a selected minimum (or maximum) affinity can be removed.
  • peptides are produced such that individual peptides have only zero or one IgE binding site.
  • Peptides with only zero or one IgE binding site may be produced by limiting the size of the peptides or by modifying larger peptides and polypeptides with multiple IgE binding sites to remove one or more of the IgE binding sites. In the absence of multiple IgE binding sites, peptides can bind to IgE antibodies but are unable to crosslink IgE antibodies bound to the surface of mast cells to trigger the release of vasodilators such as histamines.
  • a peptide which is limited by size to only single (or no) IgE binding site, or which is modified to bind to at most only one IgE antibody also prevents larger antigens from binding to that IgE antibody to crosslink to another IgE antibody.
  • the T cell stimulatory capability of the inventive compositions be preserved, and those of ordinary skill in the art will recognize that the desire to reduce IgE binding capability may be balanced against the desire to maintain T cell reactivity. Thus, for instance, it will sometimes be acceptable to leave a particular peptide in an inventive overlapping peptide composition despite significant IgE binding activity of that peptide if the presence of the peptide also confers significant T cell stimulatory capability, or other desirable feature, to the composition.
  • non-IgE-binding-site elements be preserved to the largest extent possible, e.g., by selecting overlap sizes and/or end points of fragments so that loss of information by depletion of IgE binding sites is minimized.
  • T cells stimulatory capability may or may not be preserved, but IgE-binding activity without crosslinking IgE molecules preferably is preserved.
  • Compositions comprising substantially all IgE binding sites of one or more antigens but lacking IgE crosslinking activity are particularly useful for example for passive immunotherapy treatments.
  • the particular antigen fragment collections described in Example 3 represent groups of like-sized fragments. Such uniformity is not required for the practice of the present invention. Similarly, structural overlap is not required.
  • a collection of antigen fragments (presumably of different sizes) can be designed so that each IgE binding site is split onto at least two fragments. In such circumstances, overlap between fragments should generally be minimized or removed. In fact, it may be desirable to create one or more gaps of structural information corresponding to at least part of the IgE binding site.
  • a single compound e.g.. a single protein
  • the invention can be applied to more complex allergens. Collections of more than one antigen can be used, so that immune responses to multiple antigens may be modulated simultaneously. For peptide fragments, it will often be desirable to include fragments from multiple different antigens in the composition of the present invention.
  • at least three different proteins Ara h 1. Ara h 2. and Ara h 3. are thought to contribute to peanut allergy; >90% of individuals who are allergic to peanuts have IgE reactive with Ara h 1. >90 % of allergic individuals have IgE reactive with Ara h 2.
  • compositions may include fragments from more than one of these proteins, from all of them, or from all of them plus additional peanut proteins. Also, it may be desirable to include fragments of a variety of different kinds of antigens so that multiple allergies are treated simultaneously.
  • Inventive peptide antigen fragments may be produced by any available method including but not limited to chemical or proteolytic cleavage of intact antigen, chemical synthesis, or in vitro or in vivo expression of an isolated or recombinant nucleic acid molecule. As can be seen with reference to the Appendix, a large number of genes for protein antigens have been cloned and are available for manipulation. In certain preferred embodiments, inventive peptides are prepared by chemical synthesis. Such peptides may utilize only naturally-occurring amino acids. or may include one or more non-natural amino acid analog or other chemical compound capable of being incorporated into a peptide chain.
  • compositions comprising the inventive antigen fragments may be utilized in the practice of the present invention.
  • one or more chemical groups may be linked to the antigen fragment (e.g.. a carbohydrate moiety may be linked to an amino acid).
  • inventive peptides may be produced as a fusion with another polypeptide chain.
  • Inventive antigen and antigen fragments may be provided in pure form, or may be crude preparations, such as a chemical or proteolytic digestion of a food extract (see. for example.
  • antigen to be employed in any particular composition or application will depend on the nature of the particular antigen and of the application for which it is being used, as will readily be appreciated by those of ordinary skill in the art. In general, larger amounts of antigen are useful for inducing Thl responses, smaller amounts for inducing Th2 responses.
  • the present invention provides immunomodulatory compositions containing immunostimulatory oligonucleotides and antigens as described by the present teachings. Oligonucleotides and antigens are provided in compositions with or without conjugation where conjugation is defined as association through covalent. electrostatic, or magnetic interactions. It is recognized that CpG containing oligonucleotides can be conjugated to antigenic compounds through high affinity interactions or covalent bonds. In addition, immunostimulatory oligonucleotides can be admixed with antigenic or modified antigenic compounds in accordance with the present teachings and administered to subjects and individuals in compositions without conjugation or association.
  • the immunostimulatory oligonucleotides and antigens are conjugated. Conjugation of immunostimulatory oligonucleotides and antigens is optional, however. Certain preferred collections of antigenic peptides according to the present invention may be conjugated to immunostimulatory oligonucleotides or may be provided in compositions with immunostimulatory oligonucleotides without conjugation. For compositions comprising immunostimulatory oligonucleotides and mixtures of peptides, it may be preferable not to conjugate the peptides with the oligonucleotides.
  • WO98/55495 (Schwartz et al.) teaches the conjugation of CpG containing immunostimulatory oligonucleotides to antigenic molecules. These teachings are incorporated herein by reference.
  • the immunostimulatory oligonucleotides portion can be coupled with the immunomodulatory molecule portion of a conjugate in a variety of ways, including covalent and/or non-covalent interactions.
  • the link between the portions can be made at the 3' or 5' end of the immunostimulatory oligonucleotide. or at a suitably modified base at an internal position in the immunostimulatory oligonucleotide.
  • the immunomodulatory molecule is a peptide and contains a suitable reactive group (e.g.. an N- hydroxysuccinimide ester) it can be reacted directly with the N 4 amino group of cytosine residues.
  • a suitable reactive group e.g. an N- hydroxysuccinimide ester
  • specific labeling at one or more residues can be achieved.
  • modified oligonucleosides e.g. an N- hydroxysuccinimide ester
  • the immunostimulatory oligonucleotide portion can be added to a polypeptide portion that has been pre- synthesized on a support. Haralambidis et al. (1990a) Nucleic Acids Res.
  • the immunostimulatory oligonucleotide can be synthesized such that it is connected to a solid support through a cleavable linker extending from the 3 '-end. Upon chemical cleavage of the immunostimulatory oligonucleotide from the support, a terminal thiol group is left at the 3'-end of the oligonucleotide (Zuckermann et al. (1987) Nucleic Acids Res. 15:5305-5321: and Corey et al.
  • the peptide portion of the conjugate can be attached to the 5 '-end of the immunostimulatory oligonucleotides through an amine. thiol. or carboxyl group that has been incorporated into the oligonucleotide during its synthesis.
  • a linking group comprising a protected amine. thiol. or carboxyl at one end. and a phosphoramidite at the other, is covalently attached to the 5'-hydroxyl.
  • the peptide portion can be attached to a modified cytosine or uracil at any position in the immunostimulatory oligonucleotide.
  • a "linker arm” possession a latent reactive functionality, such as an amine or carboxyl group, at C-5 of the modified base provides a handle for the peptide linkage. Ruth. 4th Annual Congress for Recombinant DNA Research, p. 123.
  • An immunostimulatory oligonucleotide-immunomodulatory molecule conjugate can also be formed through non-covalent interactions, such as ionic bonds, hydrophobic interactions, hydrogen bonds and/or van der Waals attractions.
  • Non- covalently linked conjugates can include a non-covalent interaction such as a biotin- streptavidin complex.
  • a biotinyl group can be attached, for example, to a modified base of an immunostimulatory oligonucleotide. Roget et al. (1989) Nucleic Acids Res. 17:7643-7651. Incorporation of a streptavidin moiety into the peptide portion allows formation of a non-covalently bound complex of the streptavidin conjugated peptide and the biotinylated oligonucleotide.
  • Non-covalent associations can also occur through ionic interactions involving an immunostimulatory oligonucleotide and residues within the immunomodulatory molecule, such as charged amino acids, or through the use of a linker portion comprising charged residues that can interact with both the oligonucleotide and the immunomodulatory molecule.
  • non-covalent conjugation can occur between a generally negatively-charged immunostimulatory oligonucleotides and positively-charged amino acid residues of a peptide. e.g.. polylysine and polyarginine residues.
  • an antigen can also be conjugated to immunostimulatory oligonucleotides nucleic acids by covalently or electrostatically coupling the antigen to any molecule that can bind to nucleic acids with high affinity (high affinity is defined herein as having an association constant greater than 10 6 ).
  • Non-covalent conjugation between immunostimulatory oligonucleotides and immunomodulatory molecules can occur through DNA binding motifs of molecules that interact with DNA as their natural ligands. For example, such DNA binding motifs can be found in transcription factors and anti-DNA antibodies.
  • the antigen is covalently linked to a polypeptide containing a nucleic acid binding domain.
  • the nucleic acid binding domain is a sequence-specific DNA binding domain.
  • Synthesis of fusion proteins containing an antigen and nucleic acid binding domain may be performed using recombinant DNA technology well known to one of ordinary skill in the art. Coupling of non-peptide antigens to polypeptides can be performed by chemical reactions known to those of ordinary skill in the protein chemistry art (Coligan. et al. "Current Protocols in Protein Science.” John Wiley & Sons; incorporated herein b ⁇ reference.). Non-limiting examples of molecule-nucleic acid interactions include protein-
  • nucleic acid structures that can bind molecules include G-quartets. telomeres. circular DNA and RNA (single-stranded and double- stranded), holliday junctions, cube-like structures (Seeman. "DNA nanotechnolog ⁇ : novel DNA constructions.” Annu Rev Biophys Biomol Struct. 1998. 27:225-48). RNA secondary structure, and triple-stranded nucleic acids.
  • the nucleic acid component containing the immunostimulatory oligonucleotide also contains sequences or higher order structures that serve as binding sites for the proteins coupled to antigens.
  • a preferred binding site is a sequence-specific nucleic acid binding site for a polypeptide.
  • the binding sites are not within the immunostimulatory oligonucleotide.
  • the binding between the antigen-containing component and the immunostimulatory oligonucleotide-containing component is electrostatic or magnetic.
  • the antigens are coupled to immunostimulatory oligonucleotides via electrostatic protein-nucleic acid interactions.
  • the composition designed to modulate an immune response contains at least four components.
  • the immunostimulatory oligonucleotide and the antigen constitute two components which are brought into association by the third and fourth components.
  • the third component is a nucleic acid sequence, preferably covalently linked to the immunostimulatory oligonucleotide. that contains a sequence for binding to the fourth component.
  • the nucleic acid of the third component can be DNA or RNA or derivatives thereof known to those of ordinary skill in the art and familiar with the prior art.
  • the nucleic acid of the third component can be single-stranded or double-stranded.
  • the fourth component is any molecule that can bind to the nucleic acid of the third component by electrostatic or magnetic interactions with high affinity.
  • the fourth component is a polypeptide containing a sequence-specific DNA-binding domain.
  • Many sequence-specific DNA-binding domains used in fusions proteins to target polypeptides to specific DNA sequences are well known in the art (Two-hybrid technology, Ausubel et al. "Current Protocols in Molecular Biology”. Wiley & Sons: Numerous reviews on protein-DNA interactions exist. A few are listed for incorporation by reference. Pabo CO. et al. "Transcription factors: structural families and principles of DNA recognition.” Annu Rev Biochem. 1992. 61 : 1053-95; Pabo CO. et al. "Protein-DNA recognition.” Annu Rev Biochem. 1984.
  • a composition comprises an antigen-containing component and an immunostimulatory oligonucleotide-containing component, where the association between the two components is electrostatic or magnetic. More specifically, the interaction between the two components is mediated through protein-nucleic acid interactions wherein the protein is a fusion protein comprising the antigen and a nucleic acid binding domain.
  • the fusion protein comprises the antigen and sequence-specific DNA binding domain.
  • the antigen is not a polypeptide
  • the nucleic acid-binding domain can be linked to the antigen covalently, or through electrostatic or magnetic interactions.
  • the polypeptide comprising the nucleic acid binding domain can be conjugated with the antigen through non-covalent electrostatic interactions such as a biotin-streptavidin association.
  • the linkage of the immunostimulatory oligonucleotide to a lipid can be formed using standard methods. These methods include, but are not limited to. the synthesis of oligonucleotide-phospholipid conjugated (Yanagawa et al. (1988)
  • oligonucleotide-fatty acid conjugates (Grabarek et al. (1990) Anal. Biochem. 185: 131-135; and Staros et al. (1986) Anal. Biochem. 156:220-222), and oligonucleotide-sterol conjugates. Boujrad et al. (1993) Proc. Natl. Acad. Sci. USA 90:5728-5731.
  • the linkage of the oligonucleotide to an oligosaccharide can be formed using standard known methods. These methods include, but are not limited to.
  • oligonucleotide-oligosaccharide conjugates wherein the oligosaccharide is a moiety of an immunoglobulin.
  • the linkage of a circular immunostimulatory oligonucleotides to a peptide or antigen can be formed in several ways. Where the circular immunostimulatory oligonucleotide is a synthesized using recombinant or chemical methods, a modified nucleoside is suitable. Ruth (1991 ) in Oligonucleotides and Analogues: A Practical Approach, IRL Press. Standard linking technology can then be used to connect the circular immunostimulatory oligonucleotide to the antigen or other peptide.
  • the linkage can be formed by chemically activating, or photoactivating. a reactive group (e.g. carbene. radical) that has been incorporated into the antigen or other peptide.
  • a reactive group e.g. carbene. radical
  • Oligonucleotides can be ionically. or covalently associated with appropriate molecules using techniques which are well known in the art.
  • a variety of coupling or crosslinking agents can be used e.g. protein A. carbodiimide. and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP).
  • inventive compositions comprise immunostimulatory oligonucleotides and a substantially non-allergenic compound.
  • the substantially non-allergenic compound is a compound with low. allergenicity.
  • the compound is a peptide, polypeptide or protein which can facilitate the cellular uptake of the immunostimulatory oligonucleotides.
  • non-allergenic proteins are proteins derived from the same or similar organism. For human subjects, proteins such as human serum albumin or proteins from subjects are less likely to be allergenic than proteins from other subjects or organisms. Therefore, these proteins are used in accordance with the present invention to improve the uptake of immunostimulatory oligonucleotides without utilizing antigenic compounds.
  • antigens according to the present teachings are then administered to cells or subjects stimulated by the immunostimulatory oligonucleotide-conjugate.
  • inventive methods of the present invention include treating an individual first with a composition containing CpG oligonucleotides preferably but not necessarily conjugated to a non-allergenic compound such as a protein isolated from that individual. Subsequent to. or concurrently with, administration of a CpG oligonucleotide composition, a second composition containing antigenic compounds (peptides. polypeptides.
  • the immune response of an individual or subject is first stimulated to have a Thl -type response using the CpG containing composition before administration of the antigenic compound
  • This two-step method of vaccination activates an individual " s immune system towards production of IgG and IgM antibodies and downregulates the production of IgE antibodies associated with allergic and possibly anaphylactic responses
  • the conjugates can be used for treating multiple subjects and individuals with different allergic conditions
  • the conjugation of the immunostimulatory oligonucleotides to a generally non-allergenic compound increases the number of individuals that can be treated
  • the immunostimulatory oligonucleotide and the antigen and/oi immunomodulatory facilitator can be administered together in the lorm of a conjugate or co-administered in an admixture sufficiently close in time so as to modulate an immune response
  • the immunostimulatory oligonucleotide and immunomodulatory molecule are administered simultaneousl
  • co- admimstration refers to the administration of at least two different substances sufficiently close in time to modulate an immune response
  • co-administration refers to simultaneous administration of at least two different substances
  • immunostimulatory nucleic acids and antigens are delivered to subjects or ⁇ nd ⁇ lduals using microorganisms
  • Am microorganism capable of producing immunomodulatory peptides. polypeptides. or proteins can be used in accordance with the present invention
  • the microorganism is bacterial and gram-nega e
  • gram-positive bacteria ma ⁇ also be used in the present invention
  • Non-limiting examples of bacteria include E colt Salmonella Listena Mycobacterium Legionella Vibro cholei a Shigella Yersenia Citrobacter Enterobacter Klebsiella Morganella Proteus Providencia Serratia. Plesiomonas. Aeromonas.
  • Attenuated microorganisms are infectious intracellular pathogens which are phagocytosed by antigen-presenting cells in individuals who are exposed to the microorganism.
  • infectious intracellular pathogens include Salmonella, Mycobacterium. Leishmania, Legionella. Liste ⁇ a. and Shigella.
  • microorganisms are bacteria which are genetically engineered to produce antigenic peptides, polypeptides or proteins according to the teachings of the present invention. More preferably, bacteria are killed (preferably heat-killed) or attenuated (i.e.. non-toxic strain) and administered to individuals in suitable encapsulation materials and/or as pharmaceutical compositions for vaccines.
  • compositions to subjects comprising genetically engineered bacteria which produce desired peptides. polypeptides. or proteins having amino acid sequences derived from allergenic antigens would provide immunostimulatory effects without using additional CpG-containing oligonucleotides.
  • additional CpG-containing oligonucleotides with immunostimulatory effects may be included in compositions with antigen-producing bacteria.
  • Microorganisms that can be genetically manipulated to produce a desired polypeptide by one skilled in the art are preferred (Ausubel et al. Current Protocols in Molecular Biology. Wiley and Sons. Inc. 1999. incorporated herein by reference).
  • Genetic manipulation includes mutation of the host genome, insertion of genetic material into the host genome, deletion of genetic material of the host genome. transformation of the host with extrachromosomal genetic material, transformation with linear plasmids, transformation with circular plasmids. insertion of genetic material into the host (i.e injection of mRNA), insertion of transposons. and chemical modification of genetic material.
  • Techniques for generating nucleic acids including an expressible gene, and for introducing such nucleic acids into an expression system in which any protein encoded by the expressible gene will be produced, are well established in the art (see. for example. Sambrook et al.. Molecular Cloning: A Laboratory Manual. 2nd Ed.. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY. 1989. incorporated herein by reference).
  • the microorganism is genetically engineered to produce a desired level (preferably high level) of antigenic peptides, polypeptides, or proteins and heat- killed before administration to subjects in a suitable pharmaceutical composition as a vaccine.
  • a desired level preferably high level
  • heat-killed Listeria monocytogenes is an effective adjuvant which downregulates the Th2-type immune response and upregulates the Thl -type immune response (Yeung et al. J. Immunol.
  • Listeria is also a bacterium that can be genetically manipulated to produced desired peptides and polypeptides. Therefore. Listeria is a suitable bacterium to produce peptide, polypeptide and protein antigens and is also suitable as an adjuvant for delivery to subjects. Polypeptide production by bacteria can be accomplished without secretion of the polypeptide.
  • An advantage of non-secreted polypeptide antigens is the protection afforded by the cellular membrane during a process used to kill bacteria before administration to subjects. A preferred process of killing is heat-killing.
  • any method of killing bacteria which does not degrade genetically engineered peptides, or polypeptides and hence destroy any desired physical or immunological properties of the peptides and polypeptides may be used.
  • production of polypeptides by bacteria that are highly allergenic or anaphylactic without secretion by bacteria decreases exposure of the allergens to IgE molecules when administered to subjects.
  • the polypeptides within bacteria are not released until after phagocytosis and digestion of the polypeptides by antigen-presenting cells. It is recognized that using live attenuated bacteria to produce non-secreted polypeptides also decreases exposure of the polypeptides to IgE molecules after administration to subjects.
  • Bacteria that produce and secrete inventive peptides and polypeptides according to the present teachings can also used to deliver antigenic polypeptides to subjects.
  • a variety of bacterial secretion signals that can be used in the practice of the present invention are known.
  • the Sec-dependent process in E. coli is one which is well known (for a review see Driessen et al. Curr. Opin. Microbiology 1 :216-22).
  • the OmpA signal peptide in E. coli has been described by Wong and Sutherland (US Patent 5.223,407). Fusion proteins containing either of these secretion signal peptides are not fully secreted by the bacteria, but rather only transported across the inner membrane of the gram-negative bacteria into the periplasm.
  • secretion signals may be used in the present invention to transport immunomodulatory polypeptides into the periplasm of bacteria.
  • the immunomodulatory polypeptides in the periplasm are released after degradation of the outer membrane of the bacteria in the endosome. Release of the polypeptides inside the APCs therefore reduces exposure of allergenic polypeptides to IgE antibodies bound to mast cells.
  • Bacteria that secrete inventive polypeptides into the periplasm for use in accordance with the present invention can be killed (preferably heat-killed) before administration to subjects.
  • Bacteria that secrete inventive polypeptides into the periplasm for use in accordance with the present invention can also administered to subjects as live attenuated organisms.
  • the inventive compositions are provided with one or more immune system adjuvants other than immunostimulatory oligonucleotides.
  • immune system adjuvants other than immunostimulatory oligonucleotides.
  • a large number of adjuvant compounds is known; a useful compendium of many such compounds is prepared by the National Institutes of Health and can be found on the world wide web (http:/www.niavd.nih.gov/daids/vaccine/pdt/compendium/pdf, incorporated herein by reference; see also Allison Dev. Biol. Stand. 92:3-11. 1998: Unkeless et al. Annu. Rev. Immunol. 6:251-281. 1998; and Phillips et al. Vaccine 10:151-158,1992.
  • Preferred adjuvants are characterized b> an ability to stimulate a Thl responses preferentially over Th2 responses and/or to down regulate Th2 responses.
  • adjuvants that are known to stimulate Th2 responses are avoided.
  • Particularly preferred adjuvants include, for example, preparations (including heat- killed samples, extracts, partially purified isolates, or any other preparation of a microorganism or macroorganism component sufficient to display adjuvant activity) of microorganisms such as Listeria monocytogenes or others (e.g., Bacille Calmette- Guerin [BCG]. Corynebacterium species. Mycobacterium species, Rhodococcus species.
  • the adjuvant is associated (covalently or non-covalently, directly or indirectly) with the antigen so that adjuvant and antigen can be delivered substantially simultaneously to the individual, optionally in the context of a single composition.
  • the adjuvant is provided separately. Separate adjuvants may be administered prior to. simultaneously with, or subsequent to administration of inventive antigenic compositions.
  • a separate adjuvant composition is provided that can be utilized with multiple different antigenic compositions. Where adjuvant and inventive compositions are provided together, any association sufficient to achieve the desired immunomodulatory effects may be employed.
  • covalent associations will sometimes be preferred. For example, where adjuvant and inventive peptides. polypeptides or proteins are both polypeptides. a fusion polypeptide may be employed.
  • inventive compositions may desirably be associated with a targeting entitv that will ensure their delivery to a particular desired location
  • inventive compositions are targeted for uptake by antigen presenting cells
  • inventive compositions could be targeted to dendritic cells or macrophages via association with a ligand that interacts with an uptake receptor such as the mannose receptor or an Fc receptor
  • inventive compositions comprising antigens or modified antigens conjugated to immunostimulatory oligonucleotides could be targeted to other APCs via association with a ligand that interacts with the complement receptor
  • inventive compositions comprising antigens or modified antigens could be specifically directed to dendritic cells through association with a ligand for DEC205, a mannose-hke receptor that is specific for these cells
  • inventive compositions comprising antigens or modified antigens conjugated to immunostimulatory oligonucleotides could be targeted to particular vesicles within APCs Those of ordinary skill m the art will appreciate that any targeting strategy should allow for proper uptake and processing of antigen by the APCs
  • Immunostimulatory compositions of the present invention can be targeted by association of the antigen-contammg composition with an Ig molecule, or portion thereof Ig molecules are comprised of four polypeptide chains, two identical "heavy” chains and two identical "light” chains Each chain contains an amino-termmal variable region, and a carboxy-termmal constant region
  • the four variable regions together comprise the "variable domain" of the antibody
  • the constant regions comprise the "constant domain”
  • the chains associate with one another in a Y-structure in which each short Y arm is formed by interaction of an entire light chain with the variable region and part of the constant region of one heavy chain, and the Y stem is formed by interaction of the two heavy chain constant regions with one another
  • the heavy chain constant regions determine the class of the antibody molecule, and mediate the molecule's interactions with class-specific receptors on certain target cells
  • the variable regions determine the molecule's specificity and affinity for a particular antigen Class-specific antibody receptors, with which the heavy chain constant regions interact, are found
  • inventive antigenic compositions are prepared as a fusion molecule of antigens or modified antigens with at least an Ig heavy chain constant region (e g , with an Fc fragment), so that a single polypeptide chain, containing both antigen and Ig heavy chain constant region components, is delivered to the individual (or system)
  • immunostimulatory oligonucleotides may be conjugated to the fusion molecule
  • This embodiment allows increased flexibility of antigen selection because the length and character of the antigen is not constrained by the binding requirements of the Ig variable domain cleft
  • the antigenic composition and the Fc portion of the fusion molecule are separated from one another by a severable linker that becomes cleaved when the fusion molecule is taken up into the pAPC
  • Fc fragments may be prepared by any available technique including, for example, recombinant expression (which may include expression of a fusion protein)
  • compositions of the present invention can be administered to a host via pharmaceutically acceptable compositions
  • Non-aqueous solvents include propylene glycol. polyethylene glycol. vegetable oils, and ethyl oleate.
  • Aqueous carriers include water, saline, alcoholic/aqueous solutions, emulsions or suspensions or buffered solutions.
  • Compositions for parenteral delivery include sodium chloride solutions. Ringer ' s dextrose, dextrose and NaCl solutions, lactated Ringer ' s or fixed oils.
  • Compositions for intravenous delivery include fluid and nutrient replenishers. electrolyte replenishers. Preservatives and other additives may also be utilized. These include antimicrobial agents, antioxidants. chelating agents, and inert gases.
  • Adsorption promoters for nasal drug delivery, mucosal drug delivery and skin drug delivery can facilitate adsorption of compositions into target tissues.
  • One of ordinary skill in the art may consult Chien. "Novel Drug Delivery Systems.” Marcel
  • compositions for use in accordance with the present invention may include a pharmaceutically acceptable excipient or carrier.
  • pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose, and sucrose: starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth: malt: gelatin: talc: excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil: olive oil; corn oil and soybean oil: glycols: such as propylene glycol: esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid: pyrogen-free water: isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl s
  • compositions of this invention can be administered to humans and/or to other animals, orally, rectally. parenterally. intracisternally. intravaginally. intraperitoneally. topically (as by powders, ointments, or drops), bucally. or as an oral or nasal spray.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as. for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1.3-butylene glycol. dimethylformamide. oils (in particular, cottonseed, groundnut, corn, germ, olive.
  • the oral compositions can also include adjuvants such as wetting agents, emulsfying and suspending agents, sweetening, flavoring, and perfuming agents.
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1.3-butanediol.
  • acceptable vehicles and solvents that may be employed are water. Ringer's solution. U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
  • injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of agent to polymer and the nature of the particular polymer employed, the rate of release of the agent can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches. lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as. for example, carboxymethylcellulose. alginates. gelatin, polyvinylpyrrolidinone. sucrose, and acacia, c) humectants such as glycerol. d) disintegrating agents such as agar -agar.
  • the dosage form may also comprise buffering agents.
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees. capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees. capsules, pills and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g.. tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of an inventive pharmaceutical composition include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye drops are also contemplated as being within the scope of this invention.
  • the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats. oils, waxes, paraffins, starch, tragacanth. cellulose derivatives, polyethylene glycols. silicones. bentonites. silicic acid, talc and zinc oxide, or mixtures thereof.
  • excipients such as animal and vegetable fats. oils, waxes, paraffins, starch, tragacanth. cellulose derivatives, polyethylene glycols. silicones. bentonites. silicic acid, talc and zinc oxide, or mixtures thereof.
  • Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • Transdermal patches have the added advantage of providing controlled delivery of a compound to the body.
  • dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin.
  • the rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • Colloidal dispersion systems include liposomes. nanocapsules. microspheres. beads, lipid-based systems, oil/water emulsions, micelles, and mixed micelles. Liposomes can be used as delivery vehicles for RNA. DNA, viruses and viral particles (Fraley et al. Trends Biochem. Sci. 6:11. 1981 ; Mannino et al. Biotechniques. 6:682. 1988)
  • Kits including the components of the present invention are also provided by the invention.
  • Kits may comprise components including nucleic acids, nucleic acids containing immunostimulatory sequences, antigenic molecules, nucleic acid binding molecules, antigenic molecules associated with nucleic acid-binding molecules, nucleic acids containing immunostimulatory sequences and binding sites for nucleic acid-binding molecules, pharmaceutically acceptable preparations of the preceding components and mixtures thereof.
  • nucleic acids nucleic acids containing immunostimulatory sequences, antigenic molecules, nucleic acid binding molecules, antigenic molecules associated with nucleic acid-binding molecules, nucleic acids containing immunostimulatory sequences and binding sites for nucleic acid-binding molecules, pharmaceutically acceptable preparations of the preceding components and mixtures thereof.
  • inventive compositions comprising antigens and immunostimulatory nucleic acids are provided in association with an encapsulation device (see. for example. U.S.S.N. 60/169.330 entitled “Controlled Delivery of Antigens” filed Dec. 6. 1999, incorporated by reference herewith).
  • Preferred encapsulation devices are biocompatible. are stable inside the body so that microorganisms are not released until after the encapsulation device reaches its intended destination (e.g. mucosal lining of the gut, endocytosis by antigen-presenting cells (APC)).
  • preferred systems of encapsulation are stable at physiological pH and degrade at acidic pH levels comparable to those found in the digestive tract or endosomes of APCs.
  • compositions included but are not limited to ones containing liposomes, polylactide- co-glycolide (PLGA). chitosan. synthetic biodegradable polymers, environmentally responsive hydrogels. and gelatin PLGA nanoparticles.
  • Inventive compositions may be encapsulated in combination with one or more adjuvants, targeting entities, or other agents including, for example, pharmaceutical carriers, diluents, excipients. oils, etc.
  • the encapsulation device itself may be associated with a targeting entity and/or an adjuvant.
  • the encapsulation device comprises a live, preferably attenuated, infectious organism, (i.e.. a microbe such as a bacterium or a virus)
  • infectious organism i.e.. a microbe such as a bacterium or a virus
  • Inventive antigenic compositions may be introduced into the organism by any available means.
  • the organism is genetically engineered so that it synthesizes the antigen or antigen fragments itself.
  • genetic material encoding a protein antigen or peptide antigen fragment may be introduced into the organism according to standard techniques (e.g.. transfection. transformation, electroporation. injection, etc.) so that it is expressed by the organism and the antigen or fragment produced.
  • the protein or peptide antigen is engineered to be secreted from the organism (see. for example. WO98/23763.
  • analogous systems can be engineered using any of a variety of other microbial or viral organisms. Any such system may be employed in the practice of the present invention.
  • the advantages of utilizing an organism as an encapsulation system include (i) integrity of the system prior to endocytosis. (ii) known mechanisms of endocytosis (often including targeting to particular cell types), (iii) ease of production of the delivered antigen or antigen fragments (typically made by the organism, experimental accessibility of the organisms, including ease of genetic manipulation, ability to guarantee release (e.g.. by secretion) of the antigen or antigen fragment after endocytosis. and the possibility that the encapsulating organism will also act as an adjuvant.
  • Oligonucleotides can alternatively be encapsulated in liposomes or virosomes using well-known techniques.
  • the present invention is further illustrated by the following Examples which in no way should be construed as further limiting.
  • the entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.
  • Formulations can be delivered to a patient by any available route including for example enteral, parenteral. topical (including nasal, pulmonary or other mucosal route), oral or local administration. Particularly preferred methods of administration include oral, nasal, transdermal and subcutaneous routes.
  • the compositions are preferably administered in an amount effective to elicit production of IgG while minimizing IgE mediated responses.
  • administration is preferably delivered orally.
  • compositions of the present invention may be employed to treat or prevent allergic reactions in any animal.
  • the animal is a domesticated mammal (e.g., a dog. a cat. a horse, a sheep, a pig, a goat, a cow. etc); more preferably, it is a human.
  • Any individual who suffers from allergy, or who is susceptible to allergy may be treated. It will be appreciated that an individual can be considered susceptible to allergy without having suffered an allergic reaction to the particular antigen in question. For example, if the individual has suffered an allergic reaction to a related antigen (e.g.. one from the same source or one for which shared allergies are common), that individual will be considered susceptible to allergy to the relevant antigen.
  • a related antigen e.g.. one from the same source or one for which shared allergies are common
  • any individual who is susceptible to anaphylactic shock upon exposure to food allergens, venom allergens or rubber allergens may be treated according to the present invention.
  • compositions of the present invention may be formulated for delivery by any route.
  • the compositions are formulated for injection, ingestion, or inhalation.
  • mice Female C3H/HeJ mice, 3 weeks of age (immediately after weaning), were purchased from the Jackson Laboratory (Bar Harbor. Me) and maintained on regular mouse chow under specific pathogen-free conditions. Guidelines for the care and use of the animals were followed (Institute of Laboratory Animal Resources Commission on Life Sciences, National Academy Press. 1996). Homogenized cow ' s milk (CM; GAF Seelig Inc) was used. Cholera toxin
  • CT was purchased from List Biological Laboratories. Inc (Campbell. Calif).
  • Concanavalin (Con A) and albumin, human-dinitrophenyl (DNP)-albumin were purchased from Sigma (St Louis. Mo).
  • Antibodies for ELISAs were purchased from the Binding Site Inc or PharMingen (San Diego. Calif).
  • Anti-DNP IgE was purchased from Accurate Scientific Inc.
  • mice were sensitized intragastrically with CM plus CT as an adjuvant and boosted 5 times at weekly intervals. Intragastric feeding was performed by means of a stainless steel blunt feeding needle (Fine Science Tool Inc.) To determine the optimum sensitizing dose, mice received 0.01 mg (equivalent to the milk protein contained in homogenized CM) per gram of body weight (ver low dose). 0.1 mg/g (low dose). 1.0 mg/g (medium dose), or 2 mg/g (high dose) of CM together with 0.3 ⁇ g/g of CT.
  • CM/CT mixtures were administered in PBS at a final volume of 0.03 mL/g body weight. Control mice received CT alone or were left untreated. Six weeks after the first feeding, mice were fasted over night and challenged intragastrically with 2 doses of CM (30 mg/mouse) given 30 minutes apart.
  • MEASUREMENT OF CM-SPECIFIC IGE IN SERA Blood was obtained weekly from the tail vein during the sensitization period and 1 day before challenge. Sera were collected and stored at -80 °C. Levels of CM-specific IgE were measured by ELISA as described previously (Li et al.. J Immunol. 160: 1378-84. 1998). Immulon II 96- well plates (Dynatech Laboratories. Inc.
  • the reactions were developed with TMB (Bio-Rad Laboratories, Hercules. Calif) for 30 minutes at room temperature (RT), stopped with the addition of 1 N H 2 SO 4 , and read at 450 nm.
  • the levels of IgE were calculated by comparison with a reference curve generated by using mouse mAbs (anti-DNP IgE). as previously described (Li et al.. J ImmnunoL 160: 1378-84. 1998). All analyses were performed in duplicate.
  • PLASMA HISTAMINE LEVELS Thirty minutes after challenge, blood was collected into chilled tubes containing 30 to 40 ⁇ L of 7.5% potassium-EDTA. After centrifugation (1500 rpm) for 10 minutes at 4°C, plasma aliquots were collected and frozen at - 80 °C. Histamine levels were determined by using an enzyme immunoassay kit (ImmunoTECH Inc). as described by the manufacturer. PASSIVE CUTANEOUS ANAPHYLAXIS (PCA) TEST: Sera were obtained from 4 to
  • PCA tests were performed as previously described (Saloga et al.. J. Clin. Invest. 91 : 133-40. 1993), with slight modification. Briefly, the abdomens of na ⁇ ve mice were shaved 1 day before intradermal injection of 50 ⁇ L of heated (56 °C for 3 hours) and unheated sera (1 :5 dilution). Control mice received an equal amount of diluted na ⁇ ve serum. Twenty four hours later, mice were injected intravenously with 100 ⁇ L of 0.5% Evan's blue dye, immediately followed by an intradermal injection of 50 ⁇ L of CMP (4 mg/mL).
  • mice Thirty minutes after the dye/CMP injection, the mice were killed, the skin of they belly was inverted, and reactions were examined for visible blue color. A reaction was scored as positive if the bluing of the skin at the injection sites was greater than 3 mm in diameter in any direction.
  • Serum samples 1 :20 dilution ⁇ or casein standards (8 dilutions from 30 ⁇ g/mL to 0.1 ⁇ g/mL) were incubated with rabbit anti-casein (1 : 150.000 dilution) antisera (Ross Laboratories) at 37 °C for 2 hours and were then added to the plates (100 mL/well). After incubation for 1 hour at RT, plates were washed.
  • HISTOLOGY Mast cell degranulation during systemic anaphylaxis was assessed by examination of ear samples collected immediately after anaphylaxis- related death or 40 minutes after challenge from surviving mice as previously described (Snider et al.. J. Immunol 153:647-57. 1994). Tissues were fixed in 4% phosphate-buffered formaldehyde (pH 7.2), and 5 ⁇ m paraffin sections were stained with toluidine blue or Giemsa stain. A degranulated mast cell was defined as a toluidine - or Giemsa-positive cell with 5 or more distinct stained granules completely outside of the cell.
  • jejunum and lung samples were fixed in neutral-buffered formaldehyde and embedded in paraffin.
  • Five-micrometer sections were stained with hematoxylin and eosin (H and E) and periodic acid-Schiff (PAS) reagent.
  • Mice were tested for immediate active cutaneous hypersensitivity (IACH) reactions by intradermal skin test 6 weeks after the initial sensitization with CM ( 1 mg/g plus CT). as previously described with a slight modification (Saloga et al.. J Clin Invest 91 :133-40. 1993: Hsu et al.. Clin Exp Allergy 26: 1329-37. 1996). Briefly under anesthesia the skin of the belly was shaved 1 day before the test.
  • IACH immediate active cutaneous hypersensitivity
  • CM-SPECIFIC IGE RESPONSES AFTER INTRAGASTRIC CM SENSITIZATION To investigate the kinetics of IgE production in the development of CMH. serum CM- specific IgE was monitored weekly by ELISA. Mice sensitized with the medium dose
  • CM plus CT developed significant (P > 0.01) increases in antigen-specific IgE by 3 weeks, which peaked at 6 weeks after the initial sensitization. Significantly lower levels of antigen-specific IgE were induced by both a higher dose (2 mg/g) and lower doses (0.01. 0.1 mg) of CM plus CT.
  • CHARACTERIZATION OF SYSTEMIC ANAPHYLAXIS AFTER CHALLENGE Six weeks after initial sensitization (the time of peak IgE response), the mice were challenged intragastrically with CM. Systemic anaphylactic symptoms were evident within 15 to 30 minutes. The severity of anaphylaxis was scored as indicated above.
  • mice sensitized with the medium dose ( 1 mg/g) of CM plus CT were also observed.
  • Mice sensitized with the higher and lower doses showed weaker reactions, indicating that the severity of anaphylaxis in this model was associated with the concentration of CM-specific IgE.
  • CT sham-sensitized mice and na ⁇ ve mice showed no anaphylactic reactions after CM challenge.
  • VASCULAR LEAKAGE AFTER CHALLENGE OF SENSITIZED MICE Increased vascular permeability, induced by vasoactive mediators such as histamine. is a hallmark of systemic anaphylaxis. Extensive Evan ' s blue dye extravasation was evident in footpads of CM-sensitized mice, but not CT sham-sensitized mice, after oral challenge (data not shown).
  • Plasma histamine levels were significantly increased in CM-sensitized (1 mg/g plus CT) mice (4144 ⁇ 1244 nmol/L) after challenge when compared with CT sham- sensitized (661 ⁇ 72 nmol/L) and na ⁇ ve mice (525 ⁇ 84 nmol/L). These results suggest that histamine is one of the major mediators involved in the anaphylaxis in this model.
  • CHARACTERIZATION OF INTESTINAL REACTIONS Increased intestinal permeability after intragastric CM challenge. Altered permeability was assessed in 2 ways: increased mucosal permeability by measurement of serum casein levels and increased intestinal vascular permeability by Evan ' s blue dye extravasation.
  • serum casein levels were comparable in CM-sensitized mice (41 ⁇ 20 ng/mL) and in CT control mice (42 ⁇ 12 ng/mL). However, 30 to 40 minutes after challenge, levels of serum casein in CM-sensitized mice (7890 ⁇ 256 ng mL) undergoing anaphylaxis were significantly higher than those of the control mice (205
  • HISTOLOGIC ANALYSIS OF INTESTINE Histologic examination of the small intestines revealed marked vascular congestion and edema of the lamina intestinal and. in some areas, sloughing of enterocytes at the tips of the villi (data not shown). The histologic appearance was essentially the same as that described in intestinal anaphylaxis in rats (D ' Inca et al.. Int Arch Allergy Appl Immunol 91 :270-7. 1990: Levine et al.. Int Arch Allergy Immunol 1 15:312-5. 1998). Only a small number of mast cells were observed in the intestines of normal and allergic mice, and most of these were scattered within the serosa.
  • CM-induced immediate reactions in this model were frequently accompanied by respiratory symptoms, such as wheezing and labored respiration. Histologic examination revealed that lungs from these animals were markedly inflamed and contained large numbers of perivascular and peri bronchial lymphocytes, monocytes. and eosinophils when compared with control mice (data not shown). Increased numbers of PAS- positive goblet cells were present in bronchi and bronchioles. In some instances the bronchial lumen appeared to be filled with mucus.
  • IACH INDUCTION OF IACH AFTER ORAL CM CHALLENGE IN SENSITIZED MICE It has been demonstrated that IACH reactions are associated with IgE-induced mast cell degranulation. Thus the IACH has been used for the rapid evaluation of immediate allergic reactions (Saloga et al.. J Clin Invest 91 : 133-40. 1993: Hamelmann et al., J
  • INCREASED TH2 - TYPE CYTOKINE RESPONSES To determine the role of T cells and cytokines in the development of CMA. we examined the production of cytokines by spleen cells from mice allergic to CM stimulated in vitro with CMP. After 72 hours in culture. IL-4 and IL-5 levels were significantly (P ⁇ 0.001 ) increased in
  • This Example describes the development of a mouse model system for anaphylactic peanut (PN) allergy.
  • This system may be employed in accordance with the present invention to identify and characterize compositions containing peanut antigen fragments, such as those described in the following Examples, capable of desensitizing and/or vaccinating individuals from peanut allergy.
  • mice Female C3H/HeJ mice. 5-6 weeks of age were purchased from the Jackson Laboratory (Bar Flarbor. ME) and maintained on PN-free chow, under specific pathogen-free conditions. Standard guidelines. Institute of Laboratory
  • CT Cholera Toxin
  • Concanavalin A Con A
  • albumin and human-dinitrophenyl
  • DNP- albumin human-dinitrophenyl
  • Antibodies for ELISAs were purchased from the Binding Site Inc. or Pharmingen (San Diego. CA).
  • Anti-DNP IgE was purchased from Accurate Scientific Inc. (New York).
  • mice received 5 mg/mouse (low dose), or 25 mg/mouse
  • mice were challenged ig with crude PN extract 10 mg/mouse in 2 doses at 30-40 min. intervals. Sham sensitized mice were challenged in the same manner. Mice surviving the first challenge were re-challenged at weeks 5. Additional mice were sensitized ig with Ara h 2. one of the major PN allergens. 1 mg/mouse, together with CT. and boosted 7 and 21 days later.
  • IgGl AND IgG2 Tail vein blood was obtained at weekly intervals following initial sensitization. Sera were collected and stored at - 80 °C. Levels of PN-specific IgE were measured by ELISA as described previously (Li et al., J. Immunol. 160:1378-1384. 1998). with slight modification. Briefly. Immulonll 96-well plates (Dynatech Laboratories. Inc.. Chantilly. VA) were coated with 20 ⁇ g/ml crude PN extract in coating buffer. pH 9.6 (Sigma. St. Louis. MO). After overnight incubation at 4 °C.
  • PCA tests were performed as previously described with slight modification. Briefly, the abdomens of naive mice were shaved one day prior to intradermal (id) injection of 50 ⁇ l heated (56 °C for 3 hr) or unheated sera (1 :5 dilution). Control mice received an equal amount of diluted naive serum. Twenty-four hours later, mice were injected intravenously with 100 ⁇ l of 0.5% Evan ' s blue dye. immediately followed by an id injection of 50 ⁇ l of crude PN extract (4 mg/ml). Thirty-min.
  • mice were sacrificed, the skin of the belly was inverted, and reactions were examined for visible blue color.
  • HISTOLOGY Mast cell degranulation during systemic anaphylaxis was assessed by examination of ear samples collected immediately after anaphylactic death or 40 min. after challenge from surviving mice as previously described (Li et al.. J. Immunol. 162:3045-3052.1999: Snider et al.. J. Immunol. 153:647-657. 1994). Tissues were fixed in 10% neutral buffered formalin and 5- ⁇ m toluidine blue or Giemsa stained paraffin sections from three sites of each mouse ear was examined by light microscopy at 400 X by an observer unaware of their identities. A degranulated mast cell was defined as a toluidine blue or Giemsa-positive cell with five or more distinct stained granules completely outside of the cell. Four hundred mast cells in each ear sample were classified.
  • Spleens were removed from PN sensitized and naive mice after re-challenge at week 5.
  • Spleen cells were isolated and suspended in complete culture medium (RPMI 1640 plus 10% fetal bovine serum. 1% penicillin/streptomycin, and 1% glutamine).
  • Spleen cells (1 x 10 well in 0.2 ml Bock. et al.. J. Allergy Clin. Immunol.62:327 ' -334. 1978) were incubated in triplicate cultures in microwell plates in the presence or absence of crude PN extract.
  • the first dimension consisted of an isoelectric focusing gel in glass tubing. After making the gel mixture with a pH gradient of 3.5-10 (Bio Rad Laboratories) 200 ⁇ g samples were loaded and focused with a BioRad Protean II xi 2-D cell at 200 V for 2 hours. 500 V for 2 hours and 800 V overnight.
  • the second dimension gel sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE). employed an 18% polyacrylamide separating and a 4% stacking gel as previously described (Burks et al.. J. Allergy Clin. Immunol.. 90:962-969. 1992:
  • Electrophoresis was performed for 18 hours at 25 mA per 14 cm by 12 cm gel with a set limit of 150 V in a Hoefer Apparatus (Pharmacia Biotech).
  • Proteins were transferred from the separating gel to a 0.22 ⁇ m nitrocellulose membrane in a Tris-Glycine buffer containing 20% methanol. The procedure was performed in a Hoefer transfer unit for 14 hours at 100 mA. To assure proper protein separation and quality of transfer, one nitrocellulose membrane from each pair was stained with Amido-Black. while both polyacrylamide gels were stained with Coomassie Brilliant Blue.
  • nitrocellulose membranes were placed in blocking solution (PBS containing 0.5% gelatin. 0.05% Tween and 0.001% thimerosal) overnight at RT on a rocking platform.
  • the nitrocellulose blot was then washed three times with PBS containing 0.05% Tween (PBST) and incubated with pooled sera from highly sensitive PN-allergic patients [1 : 10 dilution in a blocking solution] for two hours at RT. After rinsing and washing four times with PBST. alkaline phosphatase-conjugated goat anti-human IgE (KPL. 0.5 ⁇ g/ml) was added and incubated at RT for 2 hours.
  • KPL alkaline phosphatase-conjugated goat anti-human IgE
  • the blot was developed with BCIP/NBT Phosphatase Substrate System (KPL) for 5 min. The reaction was stopped by washing the nitrocellulose membrane with distilled water and the blot was air-dried.
  • KPL BCIP/NBT Phosphatase Substrate System
  • the blot was incubated with pooled sera from PN-sensitive mice [1 : 10 dilution] overnight at RT. followed by extensive washes with PBST and another overnight incubation in 0.75 ⁇ g/ml sheep anti-mouse IgE (The Binding Site. UK).
  • the blot was then washed 4 times and 0.3 ⁇ g/ml horseradish peroxidase conjugated donkey anti-sheep IgG (The Binding Site. UK) was added. After 2 hours incubation at RT. the blot was washed and developed with TMB Membrane Substrate Three Component System (KPL) for 15 min.. washed with distilled water, and air-dried.
  • KPL TMB Membrane Substrate Three Component System
  • mice were twice challenged ig with crude PN extract at 30-40 intervals. Systemic anaphylactic symptoms were evident within 10-15 min following the first challenge, and the severity of the anaphylaxis was evaluated at 30-40 min. after the second challenge.
  • the initial reactions were expressed as cutaneous reactions, puffiness around the eyes and mouth, and/or diarrhea followed by respiratory reactions such as wheezing and labored respiration.
  • mice sensitized with the low dose (5 mg/mouse -+- CT) of whole PN exhibited more severe reactions than those sensitized with the high dose (25 mg/mouse + CT).
  • Sham sensitized and na ⁇ ve mice did not show any symptoms of anaphylaxis.
  • KINETICS AND ISOTYPE PROFILE OF PN-SPECIFIC ANTIBODIES FOLLOWING PN-SENSITIZATION AND CHALLENGE To explore the humoral immune responses underlying the development of PN-induced hypersensitivity, sera from the different groups of mice were obtained weekly after ig sensitization and challenge. Levels of PN-specific antibody isotypes were determined by ELISA. IgE levels were significantly increased at week 1 through week 5 in mice sensitized with low dose PN (5 mg/mouse). and from week 2 through week 5 in mice sensitized high dose PN (25 mg/mouse). Furthermore, specific IgE levels in the low dose group were significantly- higher than in the high dose at both week 3 (initial challenge) and week 5 (re- challenge), suggesting an association between IgE levels and severity of anaphylactic reactions.
  • PN-specific IgGl levels were not significantly different between the high and low dose groups at weeks 3 and 5 (data not shown), suggesting that IgGl was not associated with PN-hypersensitivity reactions in this model.
  • IgG2a levels in the high dose group were significantly higher than in the low dose group at both weeks 3 and 5 (data not show) suggesting that IgG2a was inversely related with the induction of PN-hypersensitivity.
  • PCA REACTIONS Since Ag-specific IgE levels appeared positively correlated with the severity of anaphylaxis. we hypothesized that IgE was responsible for the induction of PN hypersensitivity in this model. To confirm this possibility, and to rule out IgG 1 -mediated anaphylaxis. which is known to occur in mice, PCA testing was performed. Injection of immune sera from PN allergic mice, but not heat- inactivated immune sera, induced PCA reactions (Table 1). Elimination of PCA reactions by heat inactivation of immune sera demonstrated that IgE is the reagenic antibodv in this model.
  • T-CELL PROLIFERATIVE RESPONSES TO WHOLE PN AND THE MAJOR PN ALLERGENS ARA H 1 AND ARA H 2 RESEMBLE THOSE OF HUMAN PNA To characterize T cell responses to whole PN. or major PN allergens in this model, spleen cells from PN-allergic mice or na ⁇ ve mice were cultured with crude PN extract. Ara h 1. or Ara h 2. Although cells from both PN-allergic mice and na ⁇ ve mice showed significant prohferative responses to Con A stimulation, cells from PN allergic mice, but not from na ⁇ ve mice, exhibited significant prohferative responses to PN. Ara h 1. and Ara h 2 stimulation. These results demonstrated that the T cells responses to PN and the major PN allergens were similar to those observed in PN allergic patients (Shin et al.. J. Biol. Chem. 273: 13753-13759. 1998).
  • mouse IgE bound no additional Ara h 2 fractions.
  • mouse IgE also recognized 2 of the 6 minor Ara h 3 isoforms recognized by human IgE.
  • This Example describes the definition and analysis of IgE binding sites within peanut protein antigens.
  • the information presented may be utilized in accordance with the present invention, for example, to prepare one or more antigen fragments, or collections thereof, lacking one or more peanut antigen IgE binding site
  • any of a variety of methods e.g.. immunoprecipitation. immunoblotting. cross- linking, etc.
  • methods can be used to map IgE binding sites in antigens (see. for example. methods described in Coligan et al. (eds) Current Protocols in Immunology. Wiley &
  • an antigen or antigen fragment (prepared by any available means such as. for example, chemical synthesis, chemical or enzymatic cleavage, etc.) is contacted with serum from one or more individuals known to have mounted an immune response against the antigen.
  • an antigen or antigen fragment is contacted with serum from one or more individuals known to have mounted an immune response against the antigen.
  • different organisms may react differently to the same antigen or antigen fragments; in certain circumstances it may be desirable to map the different IgE binding sites observed in different organisms.
  • an IgE binding site that is strongly recognized in the context of an intact antigen may not be strongly bound in an antigen fragment even though that fragment includes the region of the antigen corresponding to the binding site.
  • an antigen fragment is considered to contain an IgE binding site whenever it includes the region corresponding to an IgE binding site in the intact antigen: in other circumstances, an antigen fragment is only considered to have such a binding site if physical interaction has actually been demonstrated as described herein.
  • IGE IMMUNOBLOT ANALYSIS Membranes to be blotted were prepared either by SDS-PAGE (performed by the method of Laemmli Nature 227:680-685. 1970) of digested peanut antigen or by synthesis of antigen peptides on a derivativized cellulose membrane). SDS-PAGE gels were composed of 10% acrylamide resolving gel and 4% acrylamide stacking gel. Electrophoretic transfer and immunoblotting on nitrocellulose paper was performed by the procedures of Towbin (Proc. Natl. Acad. Sci. USA 76:4350-4354. 1979).
  • Human Ara h 2 epitopes (6) and (7), and mouse Ara h 2 epitopes (5) and (6) were considered to be immunodominant because, in each case, the two epitopes combined contributed about 40-50% of the observed IgE reactivity (as determined by densitometric analysis of the blot).
  • Human epitope (3) was also considered to be immunodominant. as it contributed as much as about 15% of the IgE reactivity. No other mouse or human epitope contributed more than about 10% of the reactivity.
  • peptides 1-9 (especially 3 and 4) and 18029 (especially 18-22 and 25-
  • One strategy for reducing the effective IgE binding activity of a collection of overlapping Ara h 2 peptides is to remove from the collection those peptide that include two or more IgE binding sites, and therefore have the ability to cross-link anti-Ara h 2 IgE molecules
  • Individual peptides could be tested for their ability to simultaneously bind to two or more IgE molecules could be identified by direct testing of IgE binding and/or cross-linking (e.g., histamine release).
  • human epitopes (6) and (7) are responsible for more than 40-50% of the IgE binding activity observed when human sera are tested against a panel of overlapping Ara h 2 peptides (see Stanley et al., Arch. Biochem. Biophys. 342:244-253, 1997, incorporated herein by reference).
  • all peptides containing part or all of these sequences are removed from the 5/20 collection discussed above, to produce a 5/20 collection depleted of major immunodominant epitopes. That is, peptides 1 1-14, corresponding to amino acids
  • 5/20 Native, Depleted for any Intact Human Sites
  • the above-described 5/20 collection of native Ara h 2 peptides is depleted for those peptides that contain an intact IgE binding site as defined above in Example 3. Such depletion removes peptides 2-13 and 22-28 from the collection.
  • This Example describes the use of a collection of antigen fragments (of the Ara h 2 protein) to desensitize individuals to peanut allergy.
  • the Example also shows desensitization using a modified Ara h 2 protein whose IgE binding sites have been disrupted.
  • the results with modified protein antigen are readily generalizable to peptide fragments, as described herein.
  • mice Female C3H/HeJ mice, 5-6 weeks of age were purchased from the Jackson Laboratory (Bar Harbor, ME) and maintained on PN-free chow, under specific pathogen-free conditions Standard guidelines for the care and use of animals was followed
  • Ara h 2 protein was purified as described by Burks et al (J Allergy Clin Immunol 8 172-179, 1992, incorporated herein by reference) Modified Ara h 2 was prepared as described in USSN 09/141,220 filed August 27, 1998, incorporated herein by reference The sequence of the modified Ara h 2 differed from that of natural Ara h 2 (altered positions are underlined) The Ara h 2 peptide collection was the 5/20 collection described above in Example 4
  • mice were treated with intranasal or subcutaneous peptide mix (either 2 ⁇ g or 20 ⁇ g), or with intranasal modified Ara h 2 (2 ⁇ g)
  • intranasal or subcutaneous peptide mix either 2 ⁇ g or 20 ⁇ g
  • intranasal modified Ara h 2 (2 ⁇ g)
  • One set of control mice was treated with intranasal wild type Ara h 2
  • another set was mock treated
  • mice were challenged orally with 5 mg of wild type Ara h 2, divided into two doses of 2 5 mg 30 mm apart
  • ASSAYS Hypersensitivity testing and IgE measurement were performed as described above in Example 2 Plasma histamine levels and airway responsiveness were also assayed, as were Ara h 2-specific IgE and IgG2 levels
  • mice that weie sensitized, desensitized, and challenged as described above in Example were rechallenged with Ara h 2 protein 3 weeks later
  • Anti-Ara h 2 IgE levels m mice exposed to native Ara h 2 rose four fold during the "desensitization period" By contrast, these IgE levels did not increase significantly in mice exposed to low or high dose peptides, and actually decreased almost two-fold in mice exposed to modified Ara h 2. Moreover, significant protection from anaphylaxis was observed with both the high dose peptides and the modified protein. In order to determine whether this protection were long term, we rechallenged the mice several (three) weeks later. As shown below in Table 7, the observed protection was long term:
  • a maior barley allergen associated with baker s asthma disease is a glycosylated monome ⁇ c inhibitor of insect alpha-amylase cDNA cloning and chromosomal location of the gene Plant Molec Biol 20 451 -458
  • Latex B -serum -1,3-glucanase (Hev b 2) and a component of the microhehx (Hev b 4) are major Latex allergens J nat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et procédés destinés à moduler une réponse immune d'un individu aux antigènes. Dans l'un des aspects de cette invention, on peut prévenir ou traiter des réactions allergiques aux antigènes, qui peuvent dans certains cas provoquer l'asthme et même l'anaphylaxie, en administrant des compositions comportant des oligonucléotides immunostimulants qui possèdent des séquences CpG non méthylées. Dans un autre aspect de cette invention, on peut prévenir ou traiter ces allergies aux antigènes, surtout celles qui mènent à l'asthme et à l'anaphylaxie, en administrant des compositions comportant des oligonucléotides immunostimulants qui possèdent des séquences dinucléotidiques CpG non méthylées mais aussi un(des) antigène(s), des fragments de l'antigène et des fragments de l'antigène modifiés pour réduire les réponses immunes de type Th2. Les systèmes cellulaires destinés à l'étude de l'immunostimulation par des acides nucléiques contenant CpG comprennent des systèmes in vivo, in vitro ou ex vivo.
PCT/US2000/007213 1999-03-16 2000-03-16 Acides nucleiques immunostimulants et antigenes Ceased WO2000054803A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37601/00A AU3760100A (en) 1999-03-16 2000-03-16 Immunostimulatory nucleic acids and antigens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12459599P 1999-03-16 1999-03-16
US60/124,595 1999-03-16
US12507199P 1999-03-17 1999-03-17
US60/125,071 1999-03-17

Publications (2)

Publication Number Publication Date
WO2000054803A2 true WO2000054803A2 (fr) 2000-09-21
WO2000054803A3 WO2000054803A3 (fr) 2001-01-11

Family

ID=26822754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007213 Ceased WO2000054803A2 (fr) 1999-03-16 2000-03-16 Acides nucleiques immunostimulants et antigenes

Country Status (2)

Country Link
AU (1) AU3760100A (fr)
WO (1) WO2000054803A2 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040264A3 (fr) * 1999-12-06 2001-12-13 Panacea Pharm Llc Antigenes peptidiques
WO2001066136A3 (fr) * 2000-04-06 2001-12-27 Panacea Pharm Llc Systeme d'administration microbienne
WO2003014316A2 (fr) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO2005121166A1 (fr) * 2004-06-10 2005-12-22 Monash University Nouvelles molecules d'interaction immunitaire et leurs utilisations
EP1678303A2 (fr) * 2003-10-30 2006-07-12 Coley Pharmaceutical GmbH Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
EP1700603A3 (fr) * 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Acides nucléiques immunostimulateurs
US7250403B2 (en) 2000-03-10 2007-07-31 Dynavax Technologies Corporation Biodegradable immunomodulatory formulations and methods for use thereof
US7255868B2 (en) 2001-06-21 2007-08-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—I
US7402572B2 (en) 1994-07-15 2008-07-22 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1992635A1 (fr) 2002-12-23 2008-11-19 Dynavax Technologies Corporation Oligonucléotides à séquence immunostimulatrice et ses procédés d'utilisation
US7524828B2 (en) 1994-07-15 2009-04-28 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7615539B2 (en) 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US7741297B2 (en) 2002-02-04 2010-06-22 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US7998492B2 (en) 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
US8114419B2 (en) 2002-07-03 2012-02-14 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2005252268B2 (en) * 2004-06-10 2012-06-28 Aravax Pty Limited Novel immunointeractive molecules and uses thereof
US8333980B2 (en) 1999-08-19 2012-12-18 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
US8372413B2 (en) 2000-12-27 2013-02-12 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US8574564B2 (en) 2005-12-14 2013-11-05 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US8580268B2 (en) 2006-09-27 2013-11-12 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US8691209B2 (en) 2001-09-14 2014-04-08 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US8871732B2 (en) 2002-12-23 2014-10-28 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages
US9539217B2 (en) 2013-04-03 2017-01-10 Allertein Therapeutics, Llc Nanoparticle compositions
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US11096994B2 (en) 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
US11266737B2 (en) 2013-09-25 2022-03-08 Aravax Pty Ltd Immunotherapeutic composition and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940805D1 (de) 1998-01-31 2009-06-10 Sinai School Medicine Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338297A (en) * 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
US5804201A (en) * 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
ATE252596T1 (de) * 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402572B2 (en) 1994-07-15 2008-07-22 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7674777B2 (en) * 1994-07-15 2010-03-09 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7524828B2 (en) 1994-07-15 2009-04-28 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8258106B2 (en) 1994-07-15 2012-09-04 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7723500B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7888327B2 (en) 1994-07-15 2011-02-15 University Of Iowa Research Foundation Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions
US7879810B2 (en) 1994-07-15 2011-02-01 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
US8173141B2 (en) 1999-02-17 2012-05-08 Csl Limited Immunogenic complexes and methods relating thereto
US8333980B2 (en) 1999-08-19 2012-12-18 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
EP1700603A3 (fr) * 1999-09-25 2007-06-13 Coley Pharmaceutical GmbH Acides nucléiques immunostimulateurs
WO2001040264A3 (fr) * 1999-12-06 2001-12-13 Panacea Pharm Llc Antigenes peptidiques
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US8124590B2 (en) 2000-03-10 2012-02-28 Dynavax Technologies Corporation Biodegradable immunomodulatory formulations and methods for use thereof
US7250403B2 (en) 2000-03-10 2007-07-31 Dynavax Technologies Corporation Biodegradable immunomodulatory formulations and methods for use thereof
US7183111B2 (en) 2000-03-10 2007-02-27 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
WO2001066136A3 (fr) * 2000-04-06 2001-12-27 Panacea Pharm Llc Systeme d'administration microbienne
US8372413B2 (en) 2000-12-27 2013-02-12 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
EP2423335A2 (fr) 2001-06-21 2012-02-29 Dynavax Technologies Corporation Composés immunomodulateurs chimères et leur procédé d'utilisation
US7255868B2 (en) 2001-06-21 2007-08-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—I
US8586555B2 (en) 2001-08-07 2013-11-19 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
WO2003014316A2 (fr) 2001-08-07 2003-02-20 Dynavax Technologies Corporation Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
US8691209B2 (en) 2001-09-14 2014-04-08 Cytos Biotechnology Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US9950055B2 (en) 2001-09-14 2018-04-24 Kuros Biosciences Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7741297B2 (en) 2002-02-04 2010-06-22 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8114419B2 (en) 2002-07-03 2012-02-14 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7998492B2 (en) 2002-10-29 2011-08-16 Coley Pharmaceutical Group, Inc. Methods and products related to treatment and prevention of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US7745606B2 (en) 2002-12-23 2010-06-29 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US10196643B2 (en) 2002-12-23 2019-02-05 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US11312965B2 (en) 2002-12-23 2022-04-26 Trisalus Life Sciences, Inc. Immunostimulatory sequence oligonucleotides and methods of using the same
EP1992635A1 (fr) 2002-12-23 2008-11-19 Dynavax Technologies Corporation Oligonucléotides à séquence immunostimulatrice et ses procédés d'utilisation
US8871732B2 (en) 2002-12-23 2014-10-28 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US9422564B2 (en) 2002-12-23 2016-08-23 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7615539B2 (en) 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
EP1678303A2 (fr) * 2003-10-30 2006-07-12 Coley Pharmaceutical GmbH Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues
AU2005252268B2 (en) * 2004-06-10 2012-06-28 Aravax Pty Limited Novel immunointeractive molecules and uses thereof
US8057800B2 (en) * 2004-06-10 2011-11-15 Circassia Limited Immunointeractive molecules and uses thereof
WO2005121166A1 (fr) * 2004-06-10 2005-12-22 Monash University Nouvelles molecules d'interaction immunitaire et leurs utilisations
US8574564B2 (en) 2005-12-14 2013-11-05 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US10358656B2 (en) 2006-06-12 2019-07-23 Kuros Biosciences Ag Oligonucleotides packaged into virus-like particles of RNA bacteriophages
US9902972B2 (en) 2006-06-12 2018-02-27 Kuros Biosciences Ag Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US9404126B2 (en) 2006-06-12 2016-08-02 Kuros Biosciences Ag Processes for packaging aggregated oligonucleotides into virus-like particles of RNA bacteriophages
US10260071B2 (en) 2006-09-27 2019-04-16 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US8580268B2 (en) 2006-09-27 2013-11-12 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
US11071776B2 (en) 2012-04-23 2021-07-27 N-Fold Llc Nanoparticles for treatment of allergy
US11096994B2 (en) 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
US11980658B2 (en) 2012-10-30 2024-05-14 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
US9999600B2 (en) 2013-04-03 2018-06-19 N-Fold Llc Nanoparticle compositions
US9539217B2 (en) 2013-04-03 2017-01-10 Allertein Therapeutics, Llc Nanoparticle compositions
US11266737B2 (en) 2013-09-25 2022-03-08 Aravax Pty Ltd Immunotherapeutic composition and uses thereof
US11986522B2 (en) 2013-09-25 2024-05-21 Ara Vax Pty Ltd Immunotherapeutic composition and uses thereof

Also Published As

Publication number Publication date
WO2000054803A3 (fr) 2001-01-11
AU3760100A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
WO2000054803A2 (fr) Acides nucleiques immunostimulants et antigenes
US8815251B2 (en) Microbial delivery system
Kayraklioglu et al. CpG oligonucleotides as vaccine adjuvants
WO2001040264A2 (fr) Antigenes peptidiques
ES2628744T3 (es) Métodos y productos para inducir inmunidad en mucosas
EP1450855B1 (fr) Suppression de reactions allergiques par administration intradermique d'allergenes conjugues avec des sous unites de toxine ou des fragments de celle-ci
US8246945B2 (en) Methods and reagents for decreasing clinical reaction to allergy
JP6406793B2 (ja) トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物
ES2645158T3 (es) Multímeros de oligonucleótidos inmunoestimuladores
JP4111403B2 (ja) 免疫刺激ポリヌクレオチド／免疫調節分子複合体
ES2307568T3 (es) Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
AU2001219510A1 (en) Microbial delivery system
US20120283421A1 (en) Methods and reagents for decreasing clinical reaction to allergy
US20050063994A1 (en) Methods and reagents for decreasing clinical reaction to allergy
WO2014187743A1 (fr) Composition immunogène de peptides de la gastrine
JP2007531510A (ja) 短い免疫調節性オリゴヌクレオチド
US10946078B2 (en) Treatment of canine atopic dermatitis
WO2002074250A2 (fr) Methodes et reactifs permettant de reduire la reaction clinique aux allergies
WO2000051647A2 (fr) Modele animal d'allergies
US20030084465A1 (en) Animal model of allergies
Larche et al. Modifying allergens and using adjuvants for specific immunotherapy
HK1100025A (en) Methods and products for inducing mucosal immunity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase